Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

20
results for

"Dong Hyun Sinn"

Article category

Keywords

Publication year

"Dong Hyun Sinn"

Editorial

Original Article

Hepatic neoplasm

Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis
Moon Haeng Hur, Yuri Cho, Do Young Kim, Jae Seung Lee, Gyoung Min Kim, Hyo-Cheol Kim, Dong Hyun Sinn, Dongho Hyun, Han Ah Lee, Yeon Seok Seo, In Joon Lee, Joong-Won Park, Yoon Jun Kim
Clin Mol Hepatol 2023;29(3):763-778.
Published online May 30, 2023
DOI: https://doi.org/10.3350/cmh.2023.0076
Background/Aims
Transarterial radioembolization (TARE) has shown promising results in treating advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). However, whether TARE can provide superior or comparable outcomes to tyrosine kinase inhibitor (TKI) in patients with HCC and PVTT remains unclear. We compared the outcomes of TARE and TKI therapy in treatment-naïve patients with locally advanced HCC and segmental or lobar PVTT.
Methods
This multicenter study included 216 patients initially treated with TARE (n=124) or TKI (sorafenib or lenvatinib; n=92) between 2011 and 2021. Baseline characteristics were balanced using propensity score matching (PSM) or inverse probability of treatment weighting (IPTW). The primary outcome was overall survival (OS). The secondary outcomes included progression-free survival (PFS) and
objective
response rate (ORR).
Results
In the unmatched cohort, the median OS of the TARE and TKI groups were 28.2 and 7.2 months, respectively (p<0.001), and the TARE group experienced significantly and independently longer OS compared to the TKI group (adjusted hazard ratio=0.41, 95% confidence interval=0.28–0.60, p<0.001). Similar results were observed in the study cohorts balanced with IPTW (p=0.003) or PSM (p=0.004). Although PFS was comparable between the two groups, the TARE group showed a trend of prolonged PFS in a subpopulation of patients with Vp1 or Vp2 PVTT (p=0.052). In the matched cohorts, the ORR of the TARE group was 53.0–56.7%, whereas that of the TKI group was 12.3–15.0%.
Conclusions
For patients with advanced HCC with segmental or lobar PVTT and well-preserved liver function, TARE may provide superior OS compared to sorafenib or lenvatinib.

Citations

Citations to this article as recorded by  Crossref logo
  • Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
    Ramanpreet Singh, Mina S. Makary
    Journal of Gastrointestinal Cancer.2025;[Epub]     CrossRef
  • Transarterial radioembolization versus atezolizumab-bevacizumab for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis
    Youngsu Park, Yuri Cho, Seung Up Kim, Aryoung Kim, Hyunjae Shin, Hyo-Cheol Kim, In Joon Lee, Gyoung Min Kim, Dongho Hyun, Yunmi Ko, Jeayeon Park, Jae Woong Yoon, Gyung Sun Lim, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan
    Diagnostic and Interventional Imaging.2025;[Epub]     CrossRef
  • Transarterial radioembolization challenges immunotherapy as first-line care for hepatocellular carcinoma with portal vein tumor thrombosis
    Anna Pellat, Maxime Barat
    Diagnostic and Interventional Imaging.2025;[Epub]     CrossRef
  • Pre-transplant downstaging strategies for hepatocellular carcinoma with portal vein tumor thrombus: Current therapies and future challenges
    Zong-Yang Li, Cheng Xie, Hong-Qiao Cai
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Radioembolization in Hepatocellular Carcinoma: Indications and Outcomes
    Bahareh Gholami, Ali Afrasiabi, Paolo Varela, Samira Gholami, Andrew Moon, Alexander Villalobos, David Mauro, Bryan Harris, Hyeon Yu, Nima Kokabi
    Journal of Gastrointestinal Cancer.2025;[Epub]     CrossRef
  • Screening the advantageous population for liver cancer undergoing yttrium-90 microsphere selective internal radiation therapy
    Licong Liang, Yuchan Liang, Wensou Huang, Yongjian Guo, Jingjun Huang, Jingwen Zhou, Liteng Lin, Xinxin Nie, Mingyue Cai, Kangshun Zhu
    Liver Research.2025;[Epub]     CrossRef
  • Radio-magnetic dual-functional microspheres for magnetic hyperthermia therapy combined with radioembolization of hepatocellular carcinoma
    Manran Wu, Dong Wang, Yu Qin, Xunhao Qi, Qian Huang, Xingwei Sun, Yong Jin, Ran Zhu, Guanglin Wang, Pengfei Rong
    Materials Today Bio.2025; 35: 102553.     CrossRef
  • Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study
    Bo Hyun Kim, Hee Chul Park, Tae Hyun Kim, Young-Hwan Koh, Jung Yong Hong, Yuri Cho, Dong Hyun Sinn, Boram Park, Joong-Won Park
    JHEP Reports.2024; 6(4): 100991.     CrossRef
  • Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma
    Hong Jun Lee, Jae Seung Lee, Hyesung So, Ja Kyung Yoon, Jin-Young Choi, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim
    Yonsei Medical Journal.2024; 65(7): 371.     CrossRef
  • Recent Hepatocellular Carcinoma Managements in Korea: Focus on the Updated Guidelines in 2022
    Yuri Cho, Bo Hyun Kim, Young-Suk Lim
    Digestive Disease Interventions.2024; 08(03): 169.     CrossRef
  • Research Progress in Predicting Hepatocellular Carcinoma with Portal Vein Tumour Thrombus in the Era of Artificial Intelligence
    Yaduo Li, Ningning Fan, Xu He, Jianjun Zhu, Jie Zhang, Ligong Lu
    Journal of Hepatocellular Carcinoma.2024; Volume 11: 1429.     CrossRef
  • Liver transplantation following two conversions in a patient with huge hepatocellular carcinoma and portal vein invasion: A case report
    Li-Cong Liang, Wen-Sou Huang, Zhao-Xiong Guo, Hong-Ji You, Yong-Jian Guo, Ming-Yue Cai, Li-Teng Lin, Guo-Ying Wang, Kang-Shun Zhu
    World Journal of Gastroenterology.2024; 30(36): 4071.     CrossRef
  • Transarterial intervention therapy combined with systemic therapy for HCC: a review of recent five-year articles
    Chao Fu, Hongsen Chen, Yifan Chen, Wenbin Liu, Guangwen Cao
    Hepatoma Research.2024;[Epub]     CrossRef
  • The Impact of Radiation Dose and Tumour Burden on Outcomes in Hepatocellular Carcinoma: 11-Year Experience in a 413-Patient Cohort Treated with Yttrium-90 Resin Microsphere Radioembolisation
    Kaina Chen, Aaron K.T. Tong, Fiona N.N. Moe, David C.E. Ng, Richard H.G. Lo, Apoorva Gogna, Sean X. Yan, Sue Ping Thang, Kelvin S.H. Loke, Nanda Karaddi Venkatanarasimha, Hian Liang Huang, Chow Wei Too, Timothy S.K. Ong, Eng Xuan Yeo, Daniel Yang Yao Peh,
    Liver Cancer.2024; : 1.     CrossRef
  • Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: Editorial on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein throm
    Jin Hyoung Kim, Gun Ha Kim, Dong Il Gwon
    Clinical and Molecular Hepatology.2024; 30(4): 659.     CrossRef
  • Unexpected Anti-tumor Effect of Selective Internal Radiation Therapy and Radiofrequency Ablation Followed by Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
    Mingzhi Hao, Hai Lan Lin, Yubin Hu, Qizhong Chen, Zhangxian Chen, Linbin Qiu, Duanyu Lin, Hui Zhang, Zuting Fang, Jingfeng Liu
    Hepatitis Monthly.2024;[Epub]     CrossRef
  • 8,895 View
  • 277 Download
  • 14 Web of Science
  • Crossref

Correspondence

Viral hepatitis

  • 5,203 View
  • 38 Download

Erratum

Editorials

Viral hepatitis

Citations

Citations to this article as recorded by  Crossref logo
  • Vibration-controlled transient elastography for significant fibrosis in treatment-naïve chronic hepatitis B patients: A systematic review and meta-analysis
    Mi Na Kim, Jihyun An, Eun Hwa Kim, Hee Yeon Kim, Han Ah Lee, Jung Hwan Yu, Young-Joo Jin, Young Eun Chon, Seung Up Kim, Dae Won Jun, Ji Won Han, Miyoung Choi
    Clinical and Molecular Hepatology.2024; 30(Suppl): S106.     CrossRef
  • Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”
    Halil Haldun Emiroglu
    Clinical and Molecular Hepatology.2023; 29(3): 812.     CrossRef
  • The Relationship between Mean Platelet Volume and Neutrophil–Lymphocyte Ratio and Liver Fibrosis in Patients with Chronic Hepatitis B
    Mehmet Onder Ekmen, Metin Uzman
    Medicina.2023; 59(7): 1287.     CrossRef
  • 7,921 View
  • 77 Download
  • 4 Web of Science
  • Crossref

Steatotic liver disease

How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease
Byeong Geun Song, Dong Hyun Sinn
Clin Mol Hepatol 2023;29(2):411-413.
Published online March 6, 2023
DOI: https://doi.org/10.3350/cmh.2023.0058

Citations

Citations to this article as recorded by  Crossref logo
  • Microemulsion co-delivering curcumin and DHA-rich algal oil alleviates nonalcoholic fatty liver disease
    Jianlin He, Weizhu Chen, Sisi Chen, Menglei Shi, Ling Lin, Yiping Zhang, Bihong Hong
    Journal of Functional Foods.2024; 112: 105998.     CrossRef
  • Liver transplantation for alcohol-related liver disease in Korea: The need for patient management guidelines
    Soon Kyu Lee
    Annals of Liver Transplantation.2024; 4(2): 40.     CrossRef
  • 6,515 View
  • 60 Download
  • 1 Web of Science
  • Crossref

Reviews

Hepatic neoplasm

Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective
Myung Ji Goh, Dong Hyun Sinn, Jong Man Kim, Min Woo Lee, Dong Ho Hyun, Jeong Il Yu, Jung Yong Hong, Moon Seok Choi
Clin Mol Hepatol 2023;29(2):197-205.
Published online January 5, 2023
DOI: https://doi.org/10.3350/cmh.2022.0404
Hepatocellular carcinoma (HCC) is a major cause of death in many countries, including South Korea. To provide useful and sensible advice for clinical management of patients with HCC, the Korean Liver Cancer Association and National Cancer Center Korea Practice Guideline Revision Committee have recently revised the practice guidelines for HCC management. However, there are some differences between practice guidelines and real-life clinical practice. In this review, we describe some key recommendations of the 2022 version of practice guidelines and the real-life clinical situation in South Korea, together with discussion about efforts needed to reduce the difference between guidelines and real-life clinical practice.

Citations

Citations to this article as recorded by  Crossref logo
  • Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma
    Young Mi Hong
    European Journal of Gastroenterology & Hepatology.2025; 37(1): 94.     CrossRef
  • Epidemiological characteristics and precise prophylaxis and control of HBV-associated primary liver cancer
    Yuqi Feng, Letian Fang, Guangwen Cao
    Hepatoma Research.2025;[Epub]     CrossRef
  • A Prospective, Multicenter, Randomized, Noninferiority Trial of Stopad® Versus Tachosil® for Hemostasis After Liver Resection
    Seung Yeon Lim, Gi Hong Choi, Jin Hong Lim, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Boram Lee, Yeshong Park, MeeYoung Kang, Jinju Kim, Hyelim Joo, Jai Young Cho
    Cancers.2025; 17(5): 757.     CrossRef
  • Reply: Intrahepatic IgA complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma
    Deok Hwa Seo, Pil Soo Sung
    Hepatology.2025; 81(4): E123.     CrossRef
  • The Association Between Hepatocellular Carcinoma and Gastrointestinal Adenocarcinoma: Is This a New Syndrome in Patients With Cirrhosis? A Case Series
    Fabrizio Bronte, Fabio D'Amato, Maria Rosa Barcellona, Giuseppe Bronte, Giuseppe Malizia, Salvatore Ialuna, Giorgio Fusco, Francesco Verderame, Enrico Bronte, Maria Grazia Bavetta
    Cancer Reports.2025;[Epub]     CrossRef
  • Roadmap for HCC Surveillance and Management in the Asia Pacific
    Masatoshi Kudo, Bui Thi Oanh, Chien-Jen Chen, Do Thi Ngat, Jacob George, Do Young Kim, Luckxawan Pimsawadi, Pisit Tangkijvanich, Raoh-Fang Pwu, Rosmawati Mohamed, Sakarn Bunnag, Sheng-Nan Lu, Sirintip Kudtiyakarn, Tatsuya Kanto, Teerha Piratvisuth, Chao-C
    Cancers.2025; 17(12): 1928.     CrossRef
  • TCR-based cellular immunotherapy for hepatocellular carcinoma: advances, challenges, and prospects
    Wanting Zeng, Wei Zhu, Guosheng Yuan, Jinzhang Chen, Zhanhui Wang, Jinlin Hou, De-Ke Jiang
    Cancer Immunology, Immunotherapy.2025;[Epub]     CrossRef
  • Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab–bevacizumab
    Heechul Nam, Dong Yun Kim, Do Young Kim, Ji Hoon Kim, Chang Wook Kim, Jaejun Lee, Keungmo Yang, Ji Won Han, Pil Soo Sung, Seung Kew Yoon, Hee Sun Cho, Hyun Yang, Si Hyun Bae, Soon Kyu Lee, Jung Hyun Kwon, Soon Woo Nam, Ahlim Lee, Do Seon Song, U Im Chang,
    Hepatology.2025;[Epub]     CrossRef
  • Subset of Child-Pugh Score 7 Shows Comparable Survival Outcomes to Child-Pugh Score 6 in Patients with Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab
    Jaejun Lee, Keungmo Yang, Ji Won Han, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Hee Sun Cho, Hyun Yang, Si Hyun Bae, Ji Hoon Kim, Heechul Nam, Chang Wook Kim, Hae Lim Lee, Hee Yeon Kim, Sung Won Lee, Ahlim Lee, Do Seon Song, Myeong Jun Song, Soon Woo
    Clinical Cancer Research.2025; 31(20): 4323.     CrossRef
  • Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion: An Inverse Probability of Treatment Weighted Analysis
    Jihoon Kim, Jin-Hyoung Kim, Byung Soo Im, Gun Ha Kim, Hee Ho Chu, Dong Il Gwon, Ji Hoon Shin, Ju Hyun Shim, Sang Min Yoon, Sehee Kim
    Cancers.2025; 18(1): 33.     CrossRef
  • The Position of Multikinase Inhibitors in the Era of Immune-Checkpoint Inhibitors for Hepatocellular Carcinoma
    Beom Kyung Kim
    Gut and Liver.2024; 18(1): 3.     CrossRef
  • Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
    Josep M. Llovet, Roser Pinyol, Mark Yarchoan, Amit G. Singal, Thomas U. Marron, Myron Schwartz, Eli Pikarsky, Masatoshi Kudo, Richard S. Finn
    Nature Reviews Clinical Oncology.2024; 21(4): 294.     CrossRef
  • High‐dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study
    Jun Sik Yoon, Ji Hoon Hong, Soo Young Park, Seung Up Kim, Hwi Young Kim, Ju Yeon Kim, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Han Ah Lee, Gi‐Ae Kim, Dong Hyun Sinn, Sung Jae Park, Youn Jae Lee, Yoon Jun Kim, Jung‐Hwan Yoon, Jeong‐Hoon Lee
    Alimentary Pharmacology & Therapeutics.2024; 59(8): 973.     CrossRef
  • Role of reimbursement and Physicians' awareness in the survival of sorafenib‐eligible advanced hepatocellular carcinoma patients
    Hui‐Ling Huang, Te‐Sheng Chang, Lariza Marie Canseco, Fan Wu, Sheng‐Nan Lu
    The Kaohsiung Journal of Medical Sciences.2024; 40(6): 589.     CrossRef
  • Limited Generalizability of Retrospective Single-Center Cohort Study in Comparison to Multicenter Cohort Study on Prognosis of Hepatocellular Carcinoma
    Ye Rim Kim, Sung Won Chung, Min-Ju Kim, Won-Mook Choi, Jonggi Choi, Danbi Lee, Han Chu Lee, Ju Hyun Shim
    Journal of Hepatocellular Carcinoma.2024; Volume 11: 1235.     CrossRef
  • Similar recurrence after curative treatment of HBV-related HCC, regardless of HBV replication activity
    Mi Na Kim, Beom Kyung Kim, Heejin Cho, Myung Ji Goh, Yun Ho Roh, Su Jong Yu, Dong Hyun Sinn, Soo Young Park, Seung Up Kim, Tyng-Yuan Jang
    PLOS ONE.2024; 19(8): e0307712.     CrossRef
  • The position of loco-regional therapy in the management of hepatocellular carcinoma with extrahepatic metastases
    Beom Kyung Kim
    Journal of Liver Cancer.2024; 24(2): 129.     CrossRef
  • Role of transarterial chemoembolization for hepatocellular carcinoma with extrahepatic metastases in the era of advancing systemic therapy
    Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Moon Seok Choi
    Journal of Liver Cancer.2024; 24(2): 243.     CrossRef
  • Primary treatments for solitary hepatocellular carcinoma ≤ 3 cm: A systematic review and network meta-analysis
    Sang-Hoon Kim, Ki-Hun Kim, Byeong-Gon Na, Sung Min Kim, Rak-Kyun Oh
    Annals of Hepato-Biliary-Pancreatic Surgery.2024; 28(4): 397.     CrossRef
  • Evolution of Liver Resection for Hepatocellular Carcinoma: Change Point Analysis of Textbook Outcome over Twenty Years
    Yeshong Park, Ho-Seong Han, Seung Yeon Lim, Hyelim Joo, Jinju Kim, MeeYoung Kang, Boram Lee, Hae Won Lee, Yoo-Seok Yoon, Jai Young Cho
    Medicina.2024; 61(1): 12.     CrossRef
  • A Real-World Comparative Analysis of Atezolizumab Plus Bevacizumab and Transarterial Chemoembolization Plus Radiotherapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis
    Soon Kyu Lee, Jung Hyun Kwon, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Ji Hoon Kim, Ahlim Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo Su
    Cancers.2023; 15(17): 4423.     CrossRef
  • What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?
    Min Kyung Park, Yoon Jun Kim
    Clinical and Molecular Hepatology.2023; 29(2): 332.     CrossRef
  • The current trends in the health burden of primary liver cancer across the globe
    Peter Konyn, Aijaz Ahmed, Donghee Kim
    Clinical and Molecular Hepatology.2023; 29(2): 358.     CrossRef
  • Toward user-friendly and evidence-based practice guidelines for hepatocellular carcinoma
    Do Young Kim
    Clinical and Molecular Hepatology.2023; 29(2): 335.     CrossRef
  • A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma
    Yun Bin Lee, Joon Yeul Nam, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Hyo-Cheol Kim, Jin Chul Paeng, Jung-Hwan Yoon, Yoon Jun Kim
    Clinical Cancer Research.2023; 29(18): 3650.     CrossRef
  • Tips for Preparing and Practicing Thermal Ablation Therapy of Hepatocellular Carcinoma
    Yasunori Minami, Tomoko Aoki, Satoru Hagiwara, Masatoshi Kudo
    Cancers.2023; 15(19): 4763.     CrossRef
  • 9,726 View
  • 272 Download
  • 25 Web of Science
  • Crossref
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?
Myung Ji Goh, Dong Hyun Sinn
Clin Mol Hepatol 2022;28(3):380-395.
Published online January 13, 2022
DOI: https://doi.org/10.3350/cmh.2021.0366
Preclinical studies highlighted potential therapeutic applications of aspirin and statins as anticancer agents based on their pleiotropic effects. Epidemiologic studies suggested the role of aspirin and statins in the chemoprevention of hepatocellular carcinoma (HCC). However, observational data is prone to bias, and no prospective randomized trials are currently available to assess the risks and benefits of statin or aspirin therapy for chemoprevention of HCC. It is therefore important for clinicians and researchers to be aware of the quality of current evidence regarding this issue. In this review, we summarize currently available evidence to assist clinicians with their decision to use statin or aspirin and provide information for further clinical investigations.

Citations

Citations to this article as recorded by  Crossref logo
  • Reconsidering statins in MASLD: beyond cardiovascular protection to multisystem benefit
    Xiao-Dong Zhou, Vincent Wai-Sun Wong, Ming-Hua Zheng
    Gut.2026; 75(1): 192.     CrossRef
  • Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis
    Jie Wang, Kaijie Qiu, Songsheng Zhou, Yichao Gan, Keting Jiang, Donghuan Wang, Haibiao Wang
    Annals of Medicine.2025;[Epub]     CrossRef
  • Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?: Correspondence to editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after vira
    Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu
    Clinical and Molecular Hepatology.2025; 31(1): e64.     CrossRef
  • Cancer Chemoprevention: An Exploration of the Efficacy and Potential of Various Materials (Synthetic and Natural)
    Ikram Fazaa, Leila Achour, Yosr Trabelsi, Hajer Felfel, Freddy Mounsef, Chema Drira
    Middle Eastern Cancer and Oncology Journal .2025; 1(2): 23.     CrossRef
  • Statin therapy for NAFLD: Molecular underpinnings of myopathic consequences and treatment strategies
    Pratiksha Nanepag, Shubhada Mangrulkar, Aarti Shriwas, Mayur Kale, Sapana Kushwaha, Nitu Wankhede, Brijesh Taksande, Milind Umekar
    Aspects of Molecular Medicine.2025; 5: 100091.     CrossRef
  • The value of acetylation reader YEATS2 in hepatocellular carcinoma management
    Yongjie Shi, Qiwen Xiao, Weichun Xiao, Jiale Kang, Qiang Zhou, Hongyun Jia, Yimei Chen, Sicong Huang
    Scientific Reports.2025;[Epub]     CrossRef
  • Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis
    Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn
    Journal of Gastroenterology and Hepatology.2025; 40(11): 2750.     CrossRef
  • Aspirin reduces short-term mortality risk in critically ill patients with liver cirrhosis: a propensity-score matched retrospective analysis using the MIMIC-IV database
    Yu Yi, Yinghua Chen, Yawen Luo
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • The Impact of Statins on the Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib or Lenvatinib
    Ji Eun Han, Jisu Kim, Jae Youn Cheong, Soon Sun Kim, Sun Gyo Lim, Min Jae Yang, Choong-Kyun Noh, Gil Ho Lee, Jung Woo Eun, Bumhee Park, Hyo Jung Cho
    Cancers.2024; 16(2): 249.     CrossRef
  • Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma
    Jiao Wang, Chengyu Liu, Ronghua Hu, Licheng Wu, Chuanzhou Li
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real‐world multicenter cohort study
    Hyunjae Shin, Seung Up Kim, Byeong Geun Song, Youngsu Park, Yunmi Ko, Jeayeon Park, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Jung‐Hwan Yoon, Dong Hyun Sinn, Yoon Jun Kim
    Hepatology Research.2024; 54(7): 627.     CrossRef
  • SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea
    Hyo Jung Cho, Eunyoung Lee, Soon Sun Kim, Jae Youn Cheong
    Scientific Reports.2024;[Epub]     CrossRef
  • Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication
    Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu
    Clinical and Molecular Hepatology.2024; 30(3): 326.     CrossRef
  • Chemoprevention of hepatocellular carcinoma associated with metabolic dysfunction-associated steatotic liver disease: an updated review
    Averie Dickinson, Amreen Dinani, Kara Wegermann
    Hepatoma Research.2024;[Epub]     CrossRef
  • Metformin and statins and their role in reducing hepatocellular carcinoma risk: Randomized trials are needed: Editorial on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
    Paul Y. Kwo
    Clinical and Molecular Hepatology.2024; 30(4): 714.     CrossRef
  • Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy: Letter to the editor on “Statin and aspirin for chemoprevention of hepatocellular carcinoma: T
    Dorothy Cheuk-Yan Yiu, Huapeng Lin, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Ken Liu, Terry Cheuk-Fung Yip
    Clinical and Molecular Hepatology.2024; 30(4): 970.     CrossRef
  • Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks
    Amani Elshaer, Blanca C. Lizaola-Mayo
    Life.2024; 14(12): 1701.     CrossRef
  • Statin Monotherapy Not Inferior to Aspirin or Combined Aspirin and Statins Reducing the Incidences of Cirrhosis, HCC, and Mortality in MAFLD/MASH Patients: A Population Cohort Study
    Chern-Horng Lee, Yu-Han Huang, Tzu-Ju Hsu, Tzung-Hai Yen, Sen-Yung Hsieh
    International Journal of General Medicine.2024; Volume 17: 6495.     CrossRef
  • Improving Management of Portal Hypertension: The Potential Benefit of Non-Etiological Therapies in Cirrhosis
    Niccolò Bitto, Gabriele Ghigliazza, Stanislao Lavorato, Camilla Caputo, Vincenzo La Mura
    Journal of Clinical Medicine.2023; 12(3): 934.     CrossRef
  • Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma
    Yuri Cho, Bo Hyun Kim, Joong-Won Park
    Clinical and Molecular Hepatology.2023; 29(Suppl): S220.     CrossRef
  • The potential of epigallocatechin gallate in the chemoprevention and therapy of hepatocellular carcinoma
    Dongming Li, Donghui Cao, Yingnan Cui, Yuanlin Sun, Jing Jiang, Xueyuan Cao
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • MAFLD: an optimal framework for understanding liver cancer phenotypes
    Harry Crane, Cameron Gofton, Ankur Sharma, Jacob George
    Journal of Gastroenterology.2023; 58(10): 947.     CrossRef
  • AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
    Amit G. Singal, Josep M. Llovet, Mark Yarchoan, Neil Mehta, Julie K. Heimbach, Laura A. Dawson, Janice H. Jou, Laura M. Kulik, Vatche G. Agopian, Jorge A. Marrero, Mishal Mendiratta-Lala, Daniel B. Brown, William S. Rilling, Lipika Goyal, Alice C. Wei, Ta
    Hepatology.2023; 78(6): 1922.     CrossRef
  • Statin use and the risk of hepatocellular carcinoma among patients with chronic hepatitis B: an emulated target trial using longitudinal nationwide population cohort data
    Dong Hyun Sinn, Danbee Kang, Yewan Park, Hyunsoo Kim, Yun Soo Hong, Juhee Cho, Geum-Youn Gwak
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • 9,968 View
  • 203 Download
  • 24 Web of Science
  • Crossref

Original Article

Hepatic neoplasm

Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients
Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Clin Mol Hepatol 2020;26(4):516-528.
Published online September 11, 2020
DOI: https://doi.org/10.3350/cmh.2020.0016
Background/Aims
Although hepatocellular carcinoma (HCC) is notorious for its high recurrence rate, some patients do not experience recurrence for more than 5 years after resection or radiofrequency ablation for early-stage HCC. For those with five recurrence-free period, the risk of HCC recurrence within the next 5 years remains unknown.
Methods
A total of 1,451 consecutive patients (median, 55 years old; males, 79.0%; hepatitis B virus-related, 79.3%) with good liver function (Child-Pugh class A) diagnosed with early-stage HCC by Barcelona Clinic Liver Cancer Staging and received radiofrequency ablation or resection as an initial treatment between 2005 and 2010 were analyzed.
Results
During a median follow-up period of 8.1 years, 961 patients (66.2%) experienced HCC recurrence. The cumulative recurrence rates increased to 39.7%, 60.3%, and 71.0% at 2, 5, and 10 years, respectively, and did not reach a plateau. Five years after HCC diagnosis, 487 patients were alive without experiencing a recurrence. Among them, during a median of 3.9 additional years of follow-up (range, 0.1–9.0 years), 127 patients (26.1%) experienced recurrence. The next 5-year cumulative recurrence rate (5–10 years from initial diagnosis) was 27.0%. Male sex, higher fibrosis-4 scores, and alpha-fetoprotein levels at 5 years were associated with later HCC recurrence among patients who did not experience recurrence for more than 5 years.
Conclusions
The HCC recurrence rate following 5 recurrence-free years after HCC treatment was high, indicating that HCC patients warrant continued HCC surveillance, even after 5 recurrence-free years.

Citations

Citations to this article as recorded by  Crossref logo
  • Cure after surgery for hepato-pancreato-biliary cancers: A systematic review
    Marianna Maspero, Carlo Sposito, Vincenzo Mazzaferro, Giorgio Ercolani, Alessandro Cucchetti
    Digestive and Liver Disease.2025; 57(1): 1.     CrossRef
  • What Is the Optimal Locoregional Approach for Recurrent Hepatocellular Carcinoma?
    Neil B. Newman, Colin M. Court, Alexander A. Parikh
    Journal of Clinical Oncology.2025; 43(9): 1050.     CrossRef
  • Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review
    Edoardogregorio Galli, Giorgio Patelli, Federica Villa, Nicole Gri, Chiara Mazzarelli, Iacopo Mangoni, Cristiano Sgrazzutti, Silvia Ghezzi, Andrea Sartore-Bianchi, Luca Saverio Belli, Luciano De Carlis, Angelo Vanzulli, Salvatore Siena, Katia Bencardino
    Cancer Treatment Reviews.2025; 135: 102908.     CrossRef
  • Extrahepatic Recurrence After Surgical Resection of Hepatocellular Carcinoma Without Intrahepatic Recurrence: A Multi-Institutional Observational Study
    Ga Ram You, Shin Young Park, Su Hyeon Cho, Sung Bum Cho, Yang Seok Koh, Chang Hun Lee, Hoon Gil Jo, Sung Kyu Choi, Jae Hyun Yoon
    Cancers.2025; 17(9): 1417.     CrossRef
  • Mesenchymal circulating tumor cells as prognostic markers in HCC Post-Transplantation: Sirolimus as a potential therapeutic Modulator
    Jinyan Chen, Rongsen Wang, Huigang Li, Jiancai Sun, Ruijie Zhao, Jianyong Zhuo, Zuyuan Lin, Chiyu He, Xingzhu Chen, Jun Li, Leyi Chen, Xudong Yang, Xuyong Wei, Shusen Zheng, Xiao Xu, Di Lu
    European Journal of Surgical Oncology.2025; 51(9): 110147.     CrossRef
  • Predictors of long-term survival outcomes of patients with hepatocellular carcinoma without recurrence at five years after liver resection
    Cheng-Ying Hsieh, Chee-Chien Yong, Yueh-Wei Liu, Wei-Feng Li, Chih-Chi Wang, Yi-Hao Yen, Chih-Yun Lin
    Langenbeck's Archives of Surgery.2025;[Epub]     CrossRef
  • Landscape of T-cell exhaustion heterogeneity and HBV integration in virus-related HCC revealed by whole-exome, transcriptome, and single-cell sequencing
    Soon Kyu Lee, Jinyeong Lim, Joo Yeon Jhun, Jeonghyeon Moon, Hye Seon Kim, Jong Young Choi, Ho Joong Choi, Young Kyoung You, Ji Won Han, Pil Soo Sung, Kwon Yong Tak, Seung Kew Yoon, Woong-Yang Park, Mi-La Cho, Jeong Won Jang
    JHEP Reports.2025; 7(11): 101518.     CrossRef
  • Targeting STAT3 by erianin to overcome sorafenib resistance in hepatocellular carcinoma: Integrated network pharmacology with molecular docking, dynamics simulations, and in vitro validation
    Zixian Liu, Ruoning Qian, Yuanchao Feng, Ruogu Qi, Zhengguang Zhang, Fuqiong Zhou
    Biochemical and Biophysical Research Communications.2025; 778: 152348.     CrossRef
  • Relative survival among cancer survivors enrolled in private cancer insurance in Japan, using the internal insurance-enrolled population as the reference
    Makoto Hiraoka, Hayaka Uekusa, Akira Okada, Reiko Inoue, Kayo Ikeda-Kurakawa, Yusuke Otsuka, Daisuke Namiki, Ryuichi Yamamoto, Toshimasa Yamauchi, Masaomi Nangaku, Kazuhiko Ohe, Satoko Yamaguchi, Takashi Kadowaki
    International Journal of Clinical Oncology.2025; 30(11): 2178.     CrossRef
  • Machine Learning‐Based Model for Predicting Recurrence‐Free Survival After Interventional Therapy in Malnourished Hepatocellular Carcinoma Patients
    Ningning Lu, Chunwang Yuan, Bin Sun, Xiongwei Cui, Wenfeng Gao, Yonghong Zhang
    Cancer Medicine.2025;[Epub]     CrossRef
  • Comparative efficacy of postoperative adjuvant transcatheter arterial chemoembolization and hepatic artery infusion chemotherapy in patients with BCLC stage 0-B hepatocellular carcinoma at high risk of recurrence following radical resection
    Xu Feng, Yupei Ao, Jiarui Liu, Jue Yuan, Zhengrong Shi, Chengjia Tang
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Efficacy of postoperative adjuvant hepatic artery infusion chemotherapy for hepatocellular carcinoma in microvascular invasion: a propensity-matched score
    Xu Feng, Xinhua Wu, Kai Chen, Yupei Ao, Zhengrong Shi, Yixuan Gong
    Frontiers in Surgery.2025;[Epub]     CrossRef
  • Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparison to contrast-enhanced computed tomography
    Dong Wook Kim, Won Chang, So Yeon Kim, Young-Suk Lim, Jonggi Choi, Jungheum Cho, Jin-Wook Kim, Jai Young Cho, Sun Kyung Jeon, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Kyung-Suk Suh, Kwang-Woong Lee, Dong Ho Lee
    Clinical and Molecular Hepatology.2025; 31(4): 1285.     CrossRef
  • Microvascular Invasion in Hepatocellular Carcinoma (Hcc): Implications and Strategy
    Andrea Celotti, M. Bonafede, G. Baiocchi, M. Tomasoni, F. Petrelli, M. Bonomi, G. Grizzi
    Current Surgery Reports.2025;[Epub]     CrossRef
  • Current Immunotherapy Strategies and Emerging Biomarkers for the Treatment of Hepatocellular Carcinoma
    Audrey Kapelanski-Lamoureux, Anthoula Lazaris, Nicholas Meti, Peter Metrakos
    Cancers.2025; 17(23): 3870.     CrossRef
  • The therapeutic efficacy of radical resection for hepatocellular carcinoma varies markedly by tumor location: a retrospective real-world study
    Xu Feng, Yi-Qiu Wei, Jia-Rui Liu, Zheng-Rong Shi, Kai Chen, Yong-Shuang Lv
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Serum Tumor Necrosis Factor-alpha Concentration and its Prognostic Implication in Hepatocellular Carcinoma
    Vembi Rizky Fatmawati, Ulfa Kholili, Husin Thamrin, Ricky Indra Alfaray
    Biomolecular and Health Science Journal.2025; 8(2): 105.     CrossRef
  • Mechanism study of oleanolic acid derivative, K73-03, inducing cell apoptosis in hepatocellular carcinoma
    Jiaqi Wang, Chuchu Ma, Zhongyuan Tang, Zhengwu Sun, Eskandar Qaed, Xinming Chi, Jun Wang, Yazeed Jamalat, Zhaohong Geng, Zeyao Tang, Qiying Yao
    Cancer Cell International.2024;[Epub]     CrossRef
  • Machine learning-based model for predicting tumor recurrence after interventional therapy in HBV-related hepatocellular carcinoma patients with low preoperative platelet-albumin-bilirubin score
    Qi Wang, Shugui Sheng, Yiqi Xiong, Ming Han, Ronghua Jin, Caixia Hu
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Smoking as a Risk Factor for Very Late Recurrence in Surgically Resected Early-Stage Primary Hepatocellular Carcinoma
    Wei-Ru Cho, Chih-Chi Wang, Mu-Jung Tsai, Chih-Che Lin, Yi-Hao Yen, Chien Hung Chen, Yuan-Hung Kuo, Chih-Chien Yao, Chao-Hung Hung, Pao-Yuan Huang, An-Che Liu, Ming-Chao Tsai
    Clinical Medicine Insights: Oncology.2024;[Epub]     CrossRef
  • Tubuloside B, a major constituent of Cistanche deserticola, inhibits migration of hepatocellular carcinoma by inhibiting Hippo-YAP pathway
    Jie Yao, Haoqiang Wan, Jingmei Zhang, Wanying Shen, Xiaofang Wei, Chenyan Shi, Baoru Ou, Dongyu Liu, Lanlan Ge, Jia Fei, Xiaobin Zeng
    Phytomedicine.2024; 129: 155552.     CrossRef
  • Magnetic resonance elastography as a preoperative assessment for predicting intrahepatic recurrence in patients with hepatocellular carcinoma
    Jeong Hyun Lee, Jeong Ah Hwang, Kyowon Gu, Jaeseung Shin, Seungchul Han, Young Kon Kim
    Magnetic Resonance Imaging.2024; 109: 127.     CrossRef
  • Hepatic Arterial Infusion Chemotherapy vs Transcatheter Arterial Chemoembolization as Adjuvant Therapy Following Surgery for MVI-Positive Hepatocellular Carcinoma: A Multicenter Propensity Score Matching Analysis
    Yuhua Wen, Lianghe Lu, Jie Mei, Yihong Ling, Renguo Guan, Wenping Lin, Wei Wei, Rongping Guo
    Journal of Hepatocellular Carcinoma.2024; Volume 11: 665.     CrossRef
  • Bioengineered Organoids Offer New Possibilities for Liver Cancer Studies: A Review of Key Milestones and Challenges
    Abdullah Jabri, Jibran Khan, Bader Taftafa, Mohamed Alsharif, Abdulaziz Mhannayeh, Raja Chinnappan, Alaa Alzhrani, Shadab Kazmi, Mohammad Shabab Mir, Aljohara Waleed Alsaud, Ahmed Yaqinuddin, Abdullah M. Assiri, Khaled AlKattan, Yogesh K. Vashist, Dieter
    Bioengineering.2024; 11(4): 346.     CrossRef
  • Glycemic Burden and Clinical Outcomes of Early Stage Hepatocellular Carcinoma after Curative Treatment
    Hyun Joo Lee, Moon Seok Choi, Byeong Geun Song, Won Seok Kang, Geum Youn Gwak, Myung Ji Goh, Yong Han Paik, Joon Hyeok Lee, Dong Hyun Sinn
    Cancers.2024; 16(15): 2652.     CrossRef
  • TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma
    Dongbo Qiu, Tiantian Wang, Yi Xiong, Kun Li, Xiusheng Qiu, Yuan Feng, Qinghai Lian, Yunfei Qin, Kunpeng Liu, Qi Zhang, Changchang Jia
    Oncogenesis.2024;[Epub]     CrossRef
  • Stage dependent microbial dynamics in hepatocellular carcinoma and adjacent normal liver tissues
    Hee Eun Jo, Sophallika Khom, Sumi Lee, Su Hyeon Cho, Shin Young Park, Ga Ram You, Hyosin Kim, Nah Ihm Kim, Jae-Ho Jeong, Jae Hyun Yoon, Misun Yun
    Scientific Reports.2024;[Epub]     CrossRef
  • Combining transarterial chemoembolization, radiofrequency ablation, and iodine-125 seed implantation for recurrent hepatocellular carcinoma post-hepatectomy
    Yong Zhong, Li Wang, Weibin Dan, Dan Liang
    Diagnostic and Interventional Radiology.2024;[Epub]     CrossRef
  • Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    European Journal of Internal Medicine.2023; 107: 66.     CrossRef
  • Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim
    European Journal of Clinical Investigation.2023;[Epub]     CrossRef
  • Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma
    Jing Liang, Yi Bai, Fu-Shuang Ha, Ying Luo, Hui-Ting Deng, Ying-Tang Gao
    World Journal of Gastrointestinal Oncology.2023; 15(1): 1.     CrossRef
  • Correspondence on Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”
    Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim
    Clinical and Molecular Hepatology.2023; 29(1): 173.     CrossRef
  • Abbreviated MRI for Secondary Surveillance of Recurrent Hepatocellular Carcinoma After Presumed Curative Treatment
    Sun Kyung Jeon, Dong Ho Lee, Bo‐Yun Hur, Sae‐Jin Park, Se Woo Kim, Junghoan Park, Kyung‐Suk Suh, Kwang‐Woong Lee, Nam‐Joon Yi, Joon Koo Han
    Journal of Magnetic Resonance Imaging.2023; 58(5): 1375.     CrossRef
  • The Role of Ablative Techniques in the Management of Hepatocellular Carcinoma: Indications and Outcomes
    Asanda Koza, Ricky H. Bhogal, Nicos Fotiadis, Vasileios K. Mavroeidis
    Biomedicines.2023; 11(4): 1062.     CrossRef
  • Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinoma
    Xu Feng, Guo-Ying Feng, Jie Tao, Yu-Pei Ao, Xin-Hua Wu, Shi-Guai Qi, Zheng-Rong Shi
    Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10505.     CrossRef
  • Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging
    Yoon Jung Hwang, Jae Seok Bae, Youngeun Lee, Bo Yun Hur, Dong Ho Lee, Haeryoung Kim
    Clinical and Molecular Hepatology.2023; 29(3): 733.     CrossRef
  • Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA
    Shushan Zhang, Yongquan Huang, Songying Pi, Hui Chen, Feile Ye, Chaoqun Wu, Liujun Li, Qing Ye, Yuhong Lin, Zhongzhen Su
    Journal of Nanobiotechnology.2023;[Epub]     CrossRef
  • Inflammation-related prognostic markers in resected hepatocellular carcinoma
    Fabio Giannone, Nevena Slovic, Patrick Pessaux, Catherine Schuster, Thomas F. Baumert, Joachim Lupberger
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • A Real-World Comparative Study of Microwave and Radiofrequency Ablation in Treatment-Naïve and Recurrent Hepatocellular Carcinoma
    Soon Kyu Lee, Dong Jin Chung, Se Hyun Cho
    Journal of Clinical Medicine.2022; 11(2): 302.     CrossRef
  • External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2022; 14(3): 711.     CrossRef
  • Liver-specific LINC01146, a promising prognostic indicator, inhibits the malignant phenotype of hepatocellular carcinoma cells both in vitro and in vivo
    Xiaoyun Ma, Meile Mo, Chao Tan, Jennifer Hui Juan Tan, Huishen Huang, Bihu Liu, Dongping Huang, Shun Liu, Xiaoyun Zeng, Xiaoqiang Qiu
    Journal of Translational Medicine.2022;[Epub]     CrossRef
  • MicroRNA miR-124-3p suppresses proliferation and epithelial–mesenchymal transition of hepatocellular carcinoma via ARRDC1 (arrestin domain containing 1)
    Qiannan Zhao, Fen Jiang, Hui Zhuang, Yanfeng Chu, Fang Zhang, Chenghong Wang
    Bioengineered.2022; 13(4): 8255.     CrossRef
  • Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV–DNA level < 2000 IU/mL
    Hankil Lee, Sungin Jang, Sang Hoon Ahn, Beom Kyung Kim
    Hepatology International.2022; 16(2): 294.     CrossRef
  • Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area
    Bo Hyun Kim, Dahhay Lee, Kyu-Won Jung, Young-Joo Won, Hyunsoon Cho
    Clinical and Molecular Hepatology.2022; 28(2): 242.     CrossRef
  • A Radiomics Model Based on Gd-EOB-DTPA-Enhanced MRI for the Prediction of Microvascular Invasion in Solitary Hepatocellular Carcinoma ≤ 5 cm
    Chengming Qu, Qiang Wang, Changfeng Li, Qiao Xie, Ping Cai, Xiaochu Yan, Ernesto Sparrelid, Leida Zhang, Kuansheng Ma, Torkel B. Brismar
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • L-Selenocysteine induced HepG-2 cells apoptosis through reactive oxygen species-mediated signaling pathway
    Kaiying Zhang, Jingyao Su, Danyang Chen, Binger Lin, Yucan Wu, Yibing Wang, Jiapei Lei, Ruilin Zheng, Bing Zhu, Yinghua Li
    Molecular Biology Reports.2022; 49(9): 8381.     CrossRef
  • A Systematic Pan-Cancer Analysis of YY1 Aberrations and their Relationship with Clinical Outcome, Tumor Microenvironment, and Therapeutic Targets
    Xinghao Fu, Feihong Ji, Qi He, Xinguang Qiu, Fu Wang
    Journal of Immunology Research.2022; 2022: 1.     CrossRef
  • Early extrahepatic recurrence as a pivotal factor for survival after hepatocellular carcinoma resection: A 15-year observational study
    Jae Hyun Yoon, Sung Kyu Choi, Sung Bum Cho, Hee Joon Kim, Yang Seok Ko, Chung Hwan Jun
    World Journal of Gastroenterology.2022; 28(36): 5351.     CrossRef
  • Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis
    Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim, Joo Won Baik, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun
    Clinical and Molecular Hepatology.2022; 28(4): 876.     CrossRef
  • Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    Cancers.2022; 14(20): 5002.     CrossRef
  • New Evidence of Oral Branched-Chain Amino Acid Supplementation on the Prognosis of Patients With Advanced Liver Disease
    Hankil Lee, Jeong-Ju Yoo, Sang Hoon Ahn, Beom Kyung Kim
    Clinical and Translational Gastroenterology.2022; 13(12): e00542.     CrossRef
  • External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals
    Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2021; 28(6): 951.     CrossRef
  • Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
    Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
    Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123.     CrossRef
  • The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
    Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 467.     CrossRef
  • Does Neutrophil to Lymphocyte Ratio Have a Role in Identifying Cytokeratin 19-Expressing Hepatocellular Carcinoma?
    Chao-Wei Lee, Sey-En Lin, Ming-Chin Yu, Hao-Wei Kou, Cheng-Han Lee, Tony Kuo, Kuan-Chieh Lee, Hsin-I Tsai
    Journal of Personalized Medicine.2021; 11(11): 1078.     CrossRef
  • Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
    Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
    International Journal of Molecular Sciences.2021; 22(18): 10027.     CrossRef
  • Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma
    Soon Kyu Lee, Sung Won Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
    International Journal of Molecular Sciences.2021; 22(19): 10271.     CrossRef
  • Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer
    Kyung Joo Cho, Sun Yeong Shin, Hyuk Moon, Beom Kyung Kim, Simon Weonsang Ro
    Translational Oncology.2021; 14(9): 101158.     CrossRef
  • Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Journal of Viral Hepatitis.2021; 28(11): 1570.     CrossRef
  • Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2021; 13(23): 5892.     CrossRef
  • New next-generation microwave thermosphere ablation for small hepatocellular carcinoma
    Hideyuki Tamai, Jumpei Okamura
    Clinical and Molecular Hepatology.2021; 27(4): 564.     CrossRef
  • Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis
    Ying Liu, Yuzhu Wang, Xinkun Guo, Yifeng He, Jian Zhou, Qianzhou Lv, Xiaowu Huang, Xiaoyu Li
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • 10,584 View
  • 226 Download
  • 66 Web of Science
  • Crossref

Review

Viral hepatitis

Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop
Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, Eileen L. Yoon, Hana Park, Jung Hyun Kwon, Dong Hyun Sinn, Sae Hwan Lee, Jeong-Hoon Lee, Hyun Woong Lee
Clin Mol Hepatol 2020;26(4):411-429.
Published online August 28, 2020
DOI: https://doi.org/10.3350/cmh.2020.0049
Clinical practice guidelines are important for guiding the management of specific diseases by medical practitioners, trainees, and nurses. In some cases, the guidelines are utilized as a reference for health policymakers in controlling diseases with a large public impact. With this in mind, practice guidelines for the management of chronic hepatitis B (CHB) have been developed in the United States, Europe, and Asian-Pacific regions to suggest the best-fit recommendations for each social and medical circumstance. Recently, the Korean Association for the Study of the Liver published a revised version of its clinical practice guidelines for the management of CHB. The guidelines included updated information based on newly available antiviral agents, the most recent opinion on the initiation and cessation of treatment, and updates for the management of drug resistance, partial virological response, and side effects. Additionally, CHB management in specific situations was comprehensively revised. This review compares the similarities and differences among the various practice guidelines to identify unmet needs and improve future recommendations.

Citations

Citations to this article as recorded by  Crossref logo
  • Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis B
    David Z Pan, Cameron M Soulette, Abhishek Aggarwal, Dong Han, Nicholas van Buuren, Peiwen Wu, Becket Feierbach, Jaw-Town Lin, Cheng-Hao Tseng, Chi-Yi Chen, Bryan Downie, Hongmei Mo, Lauri Diehl, Li Li, Simon P Fletcher, Scott Balsitis, Ricardo Ramirez, Vi
    Gut.2025; 74(4): 628.     CrossRef
  • Limited Value of HBV‐RNA for Relapse Prediction After Nucleos(t)ide Analogue Withdrawal in HBeAg‐negative Hepatitis B Patients
    Valerie Ohlendorf, Maximilian Wübbolding, Christoph Höner zu Siederdissen, Birgit Bremer, Katja Deterding, Heiner Wedemeyer, Markus Cornberg, Benjamin Maasoumy
    Journal of Viral Hepatitis.2025;[Epub]     CrossRef
  • Overview of chronic hepatitis B management
    Angela Jun, Sherona Bau, John S. Kim, Susanne J. Phillips
    The Nurse Practitioner.2025; 50(1): 7.     CrossRef
  • Effectiveness and safety of tenofovir amibufenamide and tenofovir alafenamide in treating elderly patients diagnosed with decompensated hepatitis B cirrhosis: a retrospective cohort study
    Xinye Qiu, Yue Yin, Shibin Zhang, Wei Liu
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Decreased incidence of hepatocellular carcinoma in non‐cirrhotic and low‐viral‐load chronic hepatitis B patients treated with nucleotide/nucleoside analogs
    Tyng‐Yuan Jang, Chia‐Yen Dai
    Advances in Digestive Medicine.2025;[Epub]     CrossRef
  • Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021
    Pojsakorn Danpanichkul, Kwanjit Duangsonk, Vincent L. Chen, Preenapun Saokhieo, Disatorn Dejvajara, Banthoon Sukphutanan, Majd B. Aboona, Chawin Lopimpisuth, Yanfang Pang, Andrew F. Ibrahim, Michael B. Fallon, Daniel Q. Huang, Donghee Kim, Amit G. Singal,
    Hepatology.2025; 82(5): 1274.     CrossRef
  • Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk
    Ankur Jindal, Manoj Kumar
    Hepatology International.2025; 19(4): 701.     CrossRef
  • Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosis
    Yunmi Ko, Byeong Geun Song, Hyunjae Shin, Youngsu Park, Jeayeon Park, Min Kyung Park, Yun Bin Lee, Su Jong Yu, Dong Hyun Sinn, Yoon Jun Kim, Jung-Hwan Yoon, Seung Shin Park, Moon Haeng Hur, Jeong-Hoon Lee
    Osteoporosis International.2025; 36(8): 1391.     CrossRef
  • Besifovir dipivoxil maleate versus other antivirals in reducing hepatocellular carcinoma in chronic hepatitis B
    Jae Seung Lee, Sung Won Lee, Hae Lim Lee, Jeong-Ju Yoo, Yeon Seok Seo, Su Jong Yu, Hyung Joon Yim, Young Kul Jung, Jisu Moon, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Sang Gyune Kim, Seung Up Kim
    Scientific Reports.2025;[Epub]     CrossRef
  • Time for a globally unified chronic HBV terminology?
    Su Wang, Catherine Freeland, Seng Gee Lim, Hailemichael Desalegn, Chari Cohen, Harry L.A. Janssen
    JHEP Reports.2025; 7(12): 101570.     CrossRef
  • Chronic hepatitis B: Is it time for expanded antiviral treatment?
    Manish Manrai, Atul A Jha, Aditya V Pachisia, Saurabh Dawra
    World Journal of Virology.2025;[Epub]     CrossRef
  • Modeling the Impact of Treatment on Hepatitis B Burden: Mathematical Analysis and Simulation
    Jean Pierre II Kouenkam, Joseph Mbang, Gilbert Chendjou, Herieth Rwezaura, Jean Tchuenche
    Operations Research Forum.2025;[Epub]     CrossRef
  • Efficacy and safety of PEG-IFN α-2b and tenofovir amibufenamide in combination therapy for chronic hepatitis B
    Wen Zhao, Longcan Li, Shihui Liu, Wenjie Zhang, Yufeng Gao, Zonghao Zhao, Xiaojun Liu, Yi Luo, Dongdong Li, Chuanmiao Liu
    BMC Infectious Diseases.2025;[Epub]     CrossRef
  • Precision Management of Patients with HBV Infection
    Chih-Lin Lin, Jia-Horng Kao
    Current Hepatology Reports.2024; 23(1): 22.     CrossRef
  • Management of Hepatitis B in Pregnancy
    Jeanette Rios, Lital Aliasi-Sinai, Natalia Schmidt, Tatyana Kushner
    Current Hepatology Reports.2024; 23(2): 278.     CrossRef
  • Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in Treatment-Naïve Patients with Chronic Hepatitis B
    Tae Hyung Kim, Ji Hoon Kim, Hyung Joon Yim, Yeon Seok Seo, Sun Young Yim, Young-Sun Lee, Young Kul Jung, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun
    Gut and Liver.2024; 18(2): 305.     CrossRef
  • Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B
    Heechul Nam, Ji Won Han, Soon Kyu Lee, Hyun Yang, Hae Lim Lee, Pil Soo Sung, Myeong Jun Song, Jung Hyun Kwon, Jeong Won Jang, U‐Im Chang, Chang Wook Kim, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jin Mo Yang, Hee Yeon Kim
    Journal of Gastroenterology and Hepatology.2024; 39(8): 1673.     CrossRef
  • Hepatitis B surface antigen loss in chronic hepatitis B patients with low‐viral‐load
    Tyng‐Yuan Jang, Batbold Batsaikhan, Yo‐Chia Chen, Chia‐Yen Dai
    Journal of Gastroenterology and Hepatology.2024; 39(11): 2327.     CrossRef
  • Modern etiotropic therapy of chronic viral hepatitis B
    E. B. Bun'kova, N. A. Bileva, A. E. Bilev, M. I. Sinel'nikov
    Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH).2024; 14(4): 76.     CrossRef
  • Low level of hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in compensated cirrhotic patients
    Wei-Chun Lin, Ke Lin, Ming-Kai Li, Xiao Liu, Yi-Fei Huang, Xing Wang, Bin Wu
    World Journal of Hepatology.2024; 16(11): 1321.     CrossRef
  • Safety and efficacy of 48-week pegylated interferon-α-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study
    Zehong Wang, Xuanxuan Wang, Li Zhou, Shaoyuan Shi, Yongli Hua, Yinong Feng
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Limited stability of Hepatitis B virus RNA in plasma and serum
    Valerie Ohlendorf, Birgit Bremer, Lisa Sandmann, Carola Mix, Tammo Tergast, Markus Cornberg, Heiner Wedemeyer, Katja Deterding, Benjamin Maasoumy
    Scientific Reports.2024;[Epub]     CrossRef
  • Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
    Shenglong Lin, Wanlong Huang, Ziyuan Liao, Huaxi Ma, Wenjun Wu, Minghua Lin, Defu Huang, Haibing Gao
    Scientific Reports.2024;[Epub]     CrossRef
  • Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    European Journal of Internal Medicine.2023; 107: 66.     CrossRef
  • Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study
    Byungyoon Yun, Juyeon Oh, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim
    American Journal of Gastroenterology.2023; 118(6): 1001.     CrossRef
  • Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease”
    Won Sohn, Yong-Han Paik
    Clinical and Molecular Hepatology.2023; 29(1): 182.     CrossRef
  • Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study
    Yoonseok Lee, Seryun Bae, Ji Hoon Kim, Minjung Kwak, So Yeon Jeon, Taehyung Kim, Sun Young Yim, Young-Sun Lee, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun
    Journal of Clinical Medicine.2023; 12(2): 712.     CrossRef
  • Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis
    Han Ah Lee, Seung Up Kim, Yeon Seok Seo, Sang Hoon Ahn, Chai Hong Rim
    Hepatology Communications.2023; 7(2): e0011.     CrossRef
  • miR-548c-3p targets TRIM22 to attenuate the Peg–IFN–α therapeutic efficacy in HBeAg-positive patients with chronic hepatitis B
    Ni Lin, Long Wang, Zhaopei Guo, Shaoying Guo, Can Liu, Jinpiao Lin, Songhang Wu, Siyi Xu, Hongyan Guo, Fenglin Fang, Ya Fu, Qishui Ou
    Antiviral Research.2023; 213: 105584.     CrossRef
  • Pre-S1 Mutations as Indicated by Serum Pre-S1 Antigen Negative is Associated with an Increased Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients
    Xingxin Zhang, Chenjian Gu, Qian Wei, Yirong Cao, Weimin She, Hong Shi, Youhua Xie, Jinsheng Guo
    Journal of Hepatocellular Carcinoma.2023; Volume 10: 599.     CrossRef
  • Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase
    Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim
    Clinical and Molecular Hepatology.2023; 29(2): 482.     CrossRef
  • Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis
    Daniel Q. Huang, Nobuharu Tamaki, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Hye Won Lee, Seng Gee Lim, Tae Seop Lim, Masayuki Kurosaki, Hiroyuki Marusawa, Toshie Mashiba, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Namiki Izumi,
    Hepatology.2023; 77(5): 1746.     CrossRef
  • Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy
    Jae Seung Lee, Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Beom Seok Kim, Seung Up Kim
    Alimentary Pharmacology & Therapeutics.2023; 58(1): 99.     CrossRef
  • The urgency to expand the antiviral indications of general chronic hepatitis B patients
    Ping Fan, Lan-Qing Li, En-Qiang Chen
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study
    Lanqing Li, Jing Zhou, Yujing Li, Fada Wang, Dongmei Zhang, Menglan Wang, Yachao Tao, Enqiang Chen
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study
    Heejoon Jang, Su Jong Yu, Hong Ghi Lee, Tae Min Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Jung-Hwan Yoon, Yoon Jun Kim
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study
    Heejin Cho, Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kyu Sung Rim, Seong Gyu Hwang
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
    Beom Kyung Kim, Sang Hoon Ahn
    Journal of the Formosan Medical Association.2023; 122(12): 1238.     CrossRef
  • Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma
    Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee
    Clinical and Molecular Hepatology.2023; 29(3): 794.     CrossRef
  • Hepatocellular Carcinoma and Hepatitis: Advanced Diagnosis and Management with a Focus on the Prevention of Hepatitis B-Related Hepatocellular Carcinoma
    Soo Ryang Kim, Soo Ki Kim
    Diagnostics.2023; 13(20): 3212.     CrossRef
  • The Connection between MiR-122 and Lymphocytes in Patients Receiving Treatment for Chronic Hepatitis B Virus Infection
    Marina Manea, Dimitri Apostol, Ileana Constantinescu
    Microorganisms.2023; 11(11): 2731.     CrossRef
  • Patient Preferences and Their Influence on Chronic Hepatitis B-A Review
    Lin Zhang, Yunyue Liu, Jinping Tian
    Patient Preference and Adherence.2023; Volume 17: 3119.     CrossRef
  • Antiviral therapy reduces hepatocellular carcinoma through suppressing hepatitis B virus replication may improve ER stress, mitochondrial and metabolic dysfunctions and decrease p62 in hybridized mice with single HBV transgene and miR‐122
    Yuh‐Jin Liang, Yu‐Wei Chiou, Abby Pei‐Ting Chiu, Ming‐Shi Shiao, Wei Teng, Chin‐Wei Lin, Mei‐Ling Cheng, Yen‐Hua Huang, Kung‐Hao Liang, Chien‐Wei Su, Chi‐Yu Lai, Chih‐Li Chen, Jaw‐Ching Wu
    Journal of Medical Virology.2023;[Epub]     CrossRef
  • Air pollution impede ALT normalization in chronic hepatitis B patients treated with nucleotide/nucleoside analogues
    Tyng-Yuan Jang, Chi-Chang Ho, Chih-Da Wu, Chia-Yen Dai, Pau-Chung Chen
    Medicine.2023; 102(43): e34276.     CrossRef
  • Effectiveness and Safety of Tenofovir Alafenamide in Treatment-Naïve and Treatment-Experienced Patients with Chronic Hepatitis B: Results of a Real-World Study from China
    Lan-Qing Li, Fa-Da Wang, Jing Zhou, Meng-Lan Wang, Yachao Tao, En-Qiang Chen
    Hepatitis Monthly.2023;[Epub]     CrossRef
  • Influence of Renal Function on the Single‐Dose Pharmacokinetics of Besifovir, a Novel Antiviral Agent for theTreatment of Hepatitis B Virus Infection
    Jun Gi Hwang, Yu Kyong Kim, Young‐sim Choi, Soon Kil Kwon, Joung‐Ho Han, Min Kyu Park
    The Journal of Clinical Pharmacology.2022; 62(1): 46.     CrossRef
  • Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection
    Zhenyu Zhong, Weiting Liao, Lingyu Dai, Xiaojie Feng, Guannan Su, Yu Gao, Qiuying Wu, Peizeng Yang
    Annals of the Rheumatic Diseases.2022; 81(4): 584.     CrossRef
  • Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL
    Hye Won Lee, Soo Young Park, Yu Rim Lee, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    American Journal of Gastroenterology.2022; 117(2): 288.     CrossRef
  • Correlation of hepatitis B surface antigen expression with clinicopathological and biochemical parameters in liver biopsies: A comprehensive study
    Anil Alpsoy, Haydar Adanir, Zeynep Bayramoglu, Gulsum Ozlem Elpek
    World Journal of Hepatology.2022; 14(1): 260.     CrossRef
  • External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2022; 14(3): 711.     CrossRef
  • Translational Strategies to Eliminate Chronic Hepatitis B in Children: Prophylaxis and Management in East Asian Countries
    Ben Kang, Dae Yong Yi, Byung-Ho Choe
    Frontiers in Pediatrics.2022;[Epub]     CrossRef
  • Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis
    Seunghwan Shin, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Diagnostics.2022; 12(2): 441.     CrossRef
  • Long‐term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study
    Young Eun Chon, Soo Young Park, Seung Up Kim, Han Pyo Hong, Jae Seung Lee, Hye Won Lee, Mi Na Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2022; 29(4): 289.     CrossRef
  • A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients
    Hyung Joon Kim, Ju Hyun Kim, Jong Eun Yeon, Yeon Seok Seo, Jeong Won Jang, Yong Kyun Cho, Byoung Kuk Jang, Byung Hoon Han, Changhyeong Lee, Joon Hyeok Lee, Jung-Hwan Yoon, Kang Mo Kim, Moon Young Kim, Do Young Kim, Neung Hwa Park, Eun Young Cho, June Sung
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Hepatitis B Core-Related Antigen Is Useful for Predicting Phase and Prognosis of Hepatitis B e Antigen-Positive Patients
    Han Ah Lee, Hyun Woong Lee, Younhee Park, Hyon-Suk Kim, Yeon Seok Seo
    Journal of Clinical Medicine.2022; 11(6): 1729.     CrossRef
  • Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV–DNA level < 2000 IU/mL
    Hankil Lee, Sungin Jang, Sang Hoon Ahn, Beom Kyung Kim
    Hepatology International.2022; 16(2): 294.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2022; 28(2): 276.     CrossRef
  • Clinical Indication of Aspirin Associated With Reduced Risk of Liver Cancer in Chronic Hepatitis B: A Nationwide Cohort Study
    Byungyoon Yun, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim
    American Journal of Gastroenterology.2022; 117(5): 758.     CrossRef
  • Fibrotic burden during antiviral therapy for chronic hepatitis B, not ALT level, independently predicts liver cancer risk
    David Sooik Kim, Beom Kyung Kim, Yeon Seok Seo, Byung Seok Kim, Byoung Kuk Jang, Sang Gyune Kim, Ki Tae Suk, Jin‐Woo Lee, Soung Won Jeong, Seung Up Kim
    Liver International.2022; 42(8): 1902.     CrossRef
  • Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000‐Korean outcome study
    Jihye Lim, Jung‐Bok Lee, Jihyun An, Gi‐Won Song, Kang Mo Kim, Han Chu Lee, Ju Hyun Shim
    Journal of Viral Hepatitis.2022; 29(9): 756.     CrossRef
  • Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study
    Byungyoon Yun, Sang Hoon Ahn, Jin‐Ha Yoon, Beom Kyung Kim
    Hepatology Communications.2022; 6(9): 2455.     CrossRef
  • Association of tenofovir and entecavir use with prognosis after surgical resection for hepatitis B virus-related hepatocellular carcinoma
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    European Journal of Internal Medicine.2022; 103: 122.     CrossRef
  • [Retracted] Finite versus Indefinite Nucleos(t)ide Analogue Therapy of Patients with Chronic Hepatitis B Exhibiting Negative HBsAg Levels after Treatment
    Haixia Sun, Yinhui Liu, Yufeng Zhang, Yusheng Jie, Yuankai Wu, Zhanyi Li, Xuxia Wei, Xiangyong Li, Bing Niu
    BioMed Research International.2022;[Epub]     CrossRef
  • Validation of Hepatocellular Carcinoma Risk Prediction Models in Patients with Hepatitis B-Related Cirrhosis
    Ran Cheng, Xiaoyuan Xu
    Journal of Hepatocellular Carcinoma.2022; Volume 9: 987.     CrossRef
  • Response to Liao et al.
    Byungyoon Yun, Jin-Ha Yoon, Beom Kyung Kim
    American Journal of Gastroenterology.2022; 117(10): 1718.     CrossRef
  • Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
    Hyung Joon Yim, Ji Hoon Kim, Yong Kyun Cho, Young Oh Kweon, Hyun Chin Cho, Jae Seok Hwang, Changhyeong Lee, Moon Soo Koh, Yang-Hyun Baek, Young-Min Park, Jeong-Hoon Lee, Seung Up Kim, Min-Kyu Kang, Neung Hwa Park, June Sung Lee, Young Eun Chon, Gab Jin Ch
    Drug Design, Development and Therapy.2022; Volume 16: 3263.     CrossRef
  • Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    Cancers.2022; 14(20): 5002.     CrossRef
  • Long-Term Prediction Model for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Antiviral Therapy: Based on Data from Korean Patients
    Ji Hun Lee, Seung Kak Shin, Seong Hee Kang, Tae Hyung Kim, Hyung Joon Yim, Sun Young Yim, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Jong Eun Yeon, Oh Sang Kwon, Soon Ho Um, Kwan Soo Byun
    Journal of Clinical Medicine.2022; 11(22): 6613.     CrossRef
  • Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis
    Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim, Joo Won Baik, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun
    Clinical and Molecular Hepatology.2022; 28(4): 876.     CrossRef
  • Secondary prevention of hepatitis B virus‐related hepatocellular carcinoma with current antiviral therapies
    Jonggi Choi, Young‐Suk Lim
    The Kaohsiung Journal of Medical Sciences.2021; 37(4): 262.     CrossRef
  • External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals
    Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2021; 28(6): 951.     CrossRef
  • Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
    Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim
    Cancers.2021; 13(14): 3424.     CrossRef
  • No Uniformity in the References of Clinical Practice Guidelines for Bariatric Surgery: a Review of 3 Similar Guidelines Published in 2020.
    Mark J. R. Smeets, Ronald S. L. Liem
    Obesity Surgery.2021; 31(12): 5427.     CrossRef
  • Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Hepatology International.2021; 15(5): 1083.     CrossRef
  • Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
    Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
    Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123.     CrossRef
  • The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
    Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 467.     CrossRef
  • Critical Updates on Chronic Hepatitis B Virus Infection in 2021
    Cyriac A Philips, Rizwan Ahamed, Jinsha K Abduljaleel, Sasidharan Rajesh, Philip Augustine
    Cureus.2021;[Epub]     CrossRef
  • Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients
    David Sooik Kim, Soo Young Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Yu Rim Lee, Won Young Tak, Young Oh Kweon, Inkyung Jung, Minkyung Han, Eun Hwa Kim, Sang Hoon Ahn, Seung Up Kim
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • Novel Therapies of Hepatitis B and D
    Iman Waheed Khan, Mati Ullah Dad Ullah, Mina Choudhry, Mukarram Jamat Ali, Muhammad Ashar Ali, Sam L. K. Lam, Pir Ahmad Shah, Satinder Pal Kaur, Daryl T. Y. Lau
    Microorganisms.2021; 9(12): 2607.     CrossRef
  • Benefits and Risks of Antiviral Treatment during Pregnancy in Patients with Chronic Hepatitis B
    Yoon Seok Lee, Soo Min Bang, Young-Sun Lee
    Journal of Clinical Medicine.2021; 10(11): 2320.     CrossRef
  • Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Journal of Viral Hepatitis.2021; 28(11): 1570.     CrossRef
  • Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients
    Hye Yeon Chon, Sang Hoon Ahn, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Dong Hyun Sinn, Seung Up Kim
    Hepatology International.2021; 15(6): 1328.     CrossRef
  • Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination
    Fátima Higuera-de la Tijera, Alfredo Servín-Caamaño, Luis Servín-Abad
    World Journal of Gastroenterology.2021; 27(26): 4004.     CrossRef
  • Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2021; 13(23): 5892.     CrossRef
  • 19,886 View
  • 1,481 Download
  • 83 Web of Science
  • Crossref

Editorial

Viral hepatitis

Low-level viremia in patients undergoing antiviral therapy: Does it indicate time for a change?
Jung Hee Kim, Dong Hyun Sinn
Clin Mol Hepatol 2020;26(3):315-317.
Published online June 23, 2020
DOI: https://doi.org/10.3350/cmh.2020.0084

Citations

Citations to this article as recorded by  Crossref logo
  • Clinical Research on LLV Patients with Chronic Hepatitis B
    琳 杨
    Advances in Clinical Medicine.2023; 13(08): 13038.     CrossRef
  • 7,750 View
  • 114 Download
  • Crossref

Reviews

Viral hepatitis

Current status and strategies for the control of viral hepatitis A in Korea
Eileen L. Yoon, Dong Hyun Sinn, Hyun Woong Lee, Ji Hoon Kim
Clin Mol Hepatol 2017;23(3):196-204.
Published online September 19, 2017
DOI: https://doi.org/10.3350/cmh.2017.0034
Hepatitis A virus is one of the most frequent causes of foodborne infection, which is closely associated with sanitary conditions and hygienic practices. The clinical spectrum of acute hepatitis A is wide, ranging from mild case without any noticeable symptoms to severe case with acute liver failure leading to mortality. The severity and outcome are highly correlated with age at infection. In developing countries, most people are infected in early childhood without significant symptom. Ironically, in area where sanitary condition has improved rapidly, adults who do not have immunity for viral hepatitis A (VH-A) in early childhood is accumulating. Adults without immunity are exposed to risks of symptomatic disease and large outbreaks in society. In Korea, where hygiene has improved rapidly, acute hepatitis A is a significant health burden that needs to be managed with nationwide health policy. The incidence of symptomatic VH-A has increased since 2000 and peaked in 2009. Korea has designated hepatitis A as a group 1 nationally notifiable infectious disease in 2001. Since 2001, mandatory surveillance system has been established to detect every single case of acute hepatitis A. Universal, nationwide vaccination program for newborns was introduced in 2015. In this review, we will present the current epidemiologic status of viral hepatitis A, and evaluate the effectiveness of the current nationwide strategies for the control of viral hepatitis A in Korea. Furthermore, we presented some action proposals that can help eliminate viral hepatitis A, which is a significant health burden in Korea.

Citations

Citations to this article as recorded by  Crossref logo
  • Hepatitis A: A wake-up call!
    Anil Chandra Anand, Akash Roy
    Indian Journal of Gastroenterology.2025; 44(5): 581.     CrossRef
  • The Shifting Epidemiology of Hepatitis A in the World Health Organization Western Pacific Region
    Nina G. Gloriani, Sheriah Laine M. de Paz-Silava, Robert D. Allison, Yoshihiro Takashima, Tigran Avagyan
    Vaccines.2024; 12(2): 204.     CrossRef
  • Current perspectives of viral hepatitis
    Daisuke Usuda, Yuki Kaneoka, Rikuo Ono, Masashi Kato, Yuto Sugawara, Runa Shimizu, Tomotari Inami, Eri Nakajima, Shiho Tsuge, Riki Sakurai, Kenji Kawai, Shun Matsubara, Risa Tanaka, Makoto Suzuki, Shintaro Shimozawa, Yuta Hotchi, Ippei Osugi, Risa Katou,
    World Journal of Gastroenterology.2024; 30(18): 2402.     CrossRef
  • Hepatitis A: Viral Structure, Classification, Life Cycle, Clinical Symptoms, Diagnosis Error, and Vaccination
    Omid Gholizadeh, Sama Akbarzadeh, Mohamad Ghazanfari Hashemi, Marjan Gholami, Parya Amini, Zahra Yekanipour, Raheleh Tabatabaie, Saman Yasamineh, Parastoo Hosseini, Vahdat Poortahmasebi, Lalit Batra
    Canadian Journal of Infectious Diseases and Medical Microbiology.2023;[Epub]     CrossRef
  • Investigating the spatio-temporal variation of hepatitis A in Korea using a Bayesian model
    Jaehong Jeong, Mijeong Kim, Jungsoon Choi
    Frontiers in Public Health.2023;[Epub]     CrossRef
  • Antibody Positivity Rates of Vaccine-preventable Diseases among New Healthcare Workers in a Teaching Hospital and Affecting Factors, 2019-2023
    Eunjung Kim, Se Ju Lee, Jae Hyoung Im, Jin-Soo Lee, Jihyeon Baek
    Korean Journal of Healthcare-Associated Infection Control and Prevention.2023; 28(2): 216.     CrossRef
  • Influence of temperature and precipitation on the incidence of hepatitis A in Seoul, Republic of Korea: a time series analysis using distributed lag linear and non-linear model
    Kiook Baek, Jonghyuk Choi, Jong-Tae Park, Kyeongmin Kwak
    International Journal of Biometeorology.2022; 66(9): 1725.     CrossRef
  • Epidemiology of liver failure in Asia‐Pacific region
    Ankur Jindal, Shiv K. Sarin
    Liver International.2022; 42(9): 2093.     CrossRef
  • The chronological changes in the seroprevalence of anti-hepatitis A virus IgG from 2005 to 2019: Experience at four centers in the capital area of South Korea
    Dae Hyun Lim, Won Sohn, Jae Yoon Jeong, Hyunwoo Oh, Jae Gon Lee, Eileen L. Yoon, Tae Yeob Kim, Seungwoo Nam, Joo Hyun Sohn
    Medicine.2022; 101(48): e31639.     CrossRef
  • Hepatitis A Outbreak Characteristics: A Comparison of Regions with Different Vaccination Strategies, Spain 2010–2018
    Angela Domínguez, Carmen Varela, Núria Soldevila, Conchita Izquierdo, María Guerrero, Marina Peñuelas, Ana Martínez, Pere Godoy, Eva Borràs, Cristina Rius, Núria Torner, Ana María Avellón, Jesús Castilla
    Vaccines.2021; 9(11): 1214.     CrossRef
  • The changing gender differences in hepatitis a incidence in South Korea
    Young June Choe, Hyunjin Son
    Vaccine.2020; 38(4): 712.     CrossRef
  • Autoimmune Hepatic Failure Following Acute Hepatitis A is Accompanied by Inflammatory Conversion of Regulatory T Cells
    Galam Leem, Beom Kyung Kim, Eui-Cheol Shin, Jun Yong Park
    Yonsei Medical Journal.2020; 61(1): 100.     CrossRef
  • Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases
    Soo-Kyung Park, Chang Hwan Choi, Jaeyoung Chun, Heeyoung Lee, Eun Sun Kim, Jae Jun Park, Chan Hyuk Park, Bo-In Lee, Yunho Jung, Dong-Il Park, Do Young Kim, Hana Park, Yoon Tae Jeen
    Intestinal Research.2020; 18(1): 18.     CrossRef
  • Case Report for Severe Hepatitis A Treated in a Korean Hospital
    Sul-Ki Kim, Cheon-Hoo Jeon, Nam-Heon Lee, Jung-Hyo Cho, Chang-Gue Son
    Journal of Korean Medicine.2020; 41(4): 100.     CrossRef
  • A Model to Predict 1‐Month Risk of Transplant or Death in Hepatitis A–Related Acute Liver Failure
    Jin Dong Kim, Eun Ju Cho, Choonghyun Ahn, Sue K. Park, Jong Young Choi, Han Chu Lee, Do Young Kim, Moon Seok Choi, Hee Jung Wang, In Hee Kim, Jong Eun Yeon, Yeon Seok Seo, Won Young Tak, Moon Young Kim, Heon Ju Lee, Yun Soo Kim, Dae Won Jun, Joo Hyun Sohn
    Hepatology.2019; 70(2): 621.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2019; 25(2): 93.     CrossRef
  • Seroprevalence of Hepatitis A Virus in Pediatric Patients with Hematologic Malignancies after Chemotherapy and Hematopoietic Cell Transplantation
    Ja Un Moon, A-Luem Han, Eui Soo Lee, Seong koo Kim, Seung Beom Han, Jae Wook Lee, Nack-Gyun Chung, Bin Cho, Dae Chul Jeong, Jin Han Kang
    Infection & Chemotherapy.2019; 51(2): 183.     CrossRef
  • Perspectives on Acute Hepatitis A Control in Korea
    Seong Hee Kang, Moon Young Kim, Soon Koo Baik
    Journal of Korean Medical Science.2019;[Epub]     CrossRef
  • Causes and countermeasures for repeated outbreaks of hepatitis A among adults in Korea
    Moran Ki, Hyunjin Son, Bo Youl Choi
    Epidemiology and Health.2019; 41: e2019038.     CrossRef
  • A Case of Graves' Disease Accompanied with Acute Hepatitis A Virus Infection
    Seong Eun Hong, Jin Woo Choo, Soo Kyung Lim, Seong Jin Lee, Ji Won Park, Sung Eun Kim, Jong Hyeok Kim, Choong Kee Park
    The Korean Journal of Gastroenterology.2018; 71(6): 354.     CrossRef
  • Seroepidemiology of Hepatitis Viruses and Hepatitis B Genotypes of Female Marriage Immigrants in Korea
    Jae-Cheol Kwon, Hye Young Chang, Oh Young Kwon, Ji Hoon Park, In Soo Oh, Hyung Joon Kim, Jun Hyung Lee, Ha-Jung Roh, Hyun Woong Lee
    Yonsei Medical Journal.2018; 59(9): 1072.     CrossRef
  • 12,930 View
  • 216 Download
  • 20 Web of Science
  • Crossref

Viral hepatitis

Current status and strategies for viral hepatitis control in Korea
Dong Hyun Sinn, Eun Ju Cho, Ji Hoon Kim, Do Young Kim, Yoon Jun Kim, Moon Seok Choi
Clin Mol Hepatol 2017;23(3):189-195.
Published online September 19, 2017
DOI: https://doi.org/10.3350/cmh.2017.0033
Viral hepatitis is one of major global health challenges with increasing disease burden worldwide. Hepatitis B virus and hepatitis C virus infections are major causes of chronic liver diseases. They can lead to cirrhosis, hepatocellular carcinoma, and death in significant portion of affected people. Transmission of hepatitis B virus can be blocked by vaccination. Progression of hepatitis B virus-related liver diseases can be prevented by long-term viral suppression with effective drugs. Although vaccine for hepatitis C virus is currently unavailable, hepatitis C virus infection can be eradicated by oral direct antiviral agents. To eliminate viral hepatitis, World Health Organization (WHO) has urged countries to develop national goals and targets through reducing 90% of new infections and providing universal access to key treatment services up to 80%. This can lead to 65% reduction of viral hepatitis-related mortality. Here, we discuss some key features of viral hepatitis, strategies to control viral hepatitis suggested by WHO, and current status and strategies for viral hepatitis control in South Korea. To achieve the goal of viral hepatitis elimination by 2030 in South Korea, an independent 'viral hepatitis sector' in Centers for Disease Control & Prevention (CDC) needs to be established to organize and execute comprehensive strategy for the management of viral hepatitis in South Korea.

Citations

Citations to this article as recorded by  Crossref logo
  • A review of historical landmarks and pioneering technologies for the diagnosis of Hepatitis C Virus (HCV)
    Kajal Sharma, Meesala Krishna Murthy
    European Journal of Clinical Microbiology & Infectious Diseases.2025; 44(6): 1289.     CrossRef
  • Análise quantitativa dos casos confirmados de Hepatite B e C no Brasil entre 2013 e 2023: um estudo epidemiológico
    Lucas Souza Reis Santos, Cleyson Nascimento Silva, Augusto Cardoso da Costa de Souza, Isabella Maria da Costa Brito, Lauana Gomes, Leonardo Isaias Bernardo de Souza, Carla Viana Dendasck, Claudio Alberto Gellis de Mattos, Amanda Alves Fecury
    Revista Científica Multidisciplinar Núcleo do Conhecimento.2025; : 05.     CrossRef
  • Current perspectives of viral hepatitis
    Daisuke Usuda, Yuki Kaneoka, Rikuo Ono, Masashi Kato, Yuto Sugawara, Runa Shimizu, Tomotari Inami, Eri Nakajima, Shiho Tsuge, Riki Sakurai, Kenji Kawai, Shun Matsubara, Risa Tanaka, Makoto Suzuki, Shintaro Shimozawa, Yuta Hotchi, Ippei Osugi, Risa Katou,
    World Journal of Gastroenterology.2024; 30(18): 2402.     CrossRef
  • Experience with HCV Detection and Molecular Genetic Characterization among Otherwise Healthy Pregnant Women and Their Partners in the Republic of Guinea
    Yulia V. Ostankova, Diana E. Reingardt, Alexandr N. Schemelev, Thierno A. L. Balde, Sanaba Boumbaly, Areg A. Totolian
    Microorganisms.2024; 12(10): 1959.     CrossRef
  • Contextual and individual factors associated with knowledge, awareness and attitude on liver diseases: A large‐scale Asian study
    Mei Hsuan Lee, Sang Hoon Ahn, Henry L. Y. Chan, Asad Choudhry, Rino Alvani Gani, Rosmawati Mohamed, Janus P. Ong, Akash Shukla, Chee Kiat Tan, Tawesak Tanwandee, Pham Thi Thu Thuy, Boon Leong Neo, Venus Tsang, Jin Youn, Shikha Singh
    Journal of Viral Hepatitis.2022; 29(2): 156.     CrossRef
  • Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase
    Gyeol Seong, Dong Hyun Sinn, Wonseok Kang, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Yong-Han Paik
    European Journal of Gastroenterology & Hepatology.2022; 34(1): 69.     CrossRef
  • Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts
    Sang Il Choi, Yuri Cho, Moran Ki, Bo Hyun Kim, In Joon Lee, Tae Hyun Kim, Seong Hoon Kim, Young Hwan Koh, Hyun Beom Kim, Eun Kyung Hong, Chang-Min Kim, Joong-Won Park, Hamidreza Karimi-Sari
    PLOS ONE.2022; 17(3): e0265668.     CrossRef
  • Risk Association of Liver Cancer and Hepatitis B with Tree Ensemble and Lifestyle Features
    Eunji Koh, Younghoon Kim
    International Journal of Environmental Research and Public Health.2022; 19(22): 15171.     CrossRef
  • Role of bioactive compounds in the treatment of hepatitis: A review
    Arpita Roy, Madhura Roy, Amel Gacem, Shreeja Datta, Md. Zeyaullah, Khursheed Muzammil, Thoraya A. Farghaly, Magda H. Abdellattif, Krishna Kumar Yadav, Jesus Simal-Gandara
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Study on Quality Markers and Action Mechanisms of Inulae Flos on Anti-Hepatitis Through Network Pharmacology and High-Performance Liquid Chromatography Fingerprints
    Li Lin, Lian-Lin Su, Huan-Huan Li, Chun-Qin Mao, De Ji, Hui Xie, Tu-Lin Lu
    World Journal of Traditional Chinese Medicine.2022; 8(3): 426.     CrossRef
  • Interleukin-35: An emerging player in the progression of liver diseases
    Na Zhao, Xin Liu, Hao Guo, Xiangnan Zhao, Yujie Qiu, Wei Wang
    Clinics and Research in Hepatology and Gastroenterology.2021; 45(1): 101518.     CrossRef
  • Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study
    Dong Hyun Sinn, Danbee Kang, Yun Soo Hong, Kwang Cheol Koh, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak, Luca Rinaldi
    PLOS ONE.2021; 16(8): e0255624.     CrossRef
  • Differential Effectiveness of Tenofovir and Entecavir for Prophylaxis of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Depending on Coexisting Cirrhosis and Prior Exposure to Antiviral Therapy
    Seogsong Jeong, Yuri Cho, Sang Min Park, Won Kim
    Journal of Clinical Gastroenterology.2021; 55(9): e77.     CrossRef
  • Current and future strategies for the treatment of chronic hepatitis C
    Omar Alshuwaykh, Paul Y. Kwo
    Clinical and Molecular Hepatology.2021; 27(2): 246.     CrossRef
  • Alcohol Intake and Mortality in Patients With Chronic Viral Hepatitis: A Nationwide Cohort Study
    Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Yoosoo Chang, Seungho Ryu, Di Zhao, Yun Soo Hong, Juhee Cho, Geum-Youn Gwak
    American Journal of Gastroenterology.2021; 116(2): 329.     CrossRef
  • Viral hepatitis: A brief introduction, review of management, advances and challenges
    Olga Fagan, Paul Amstrong, Kevin Van Der Merwe, Daniela Crosnoi, Chris Steele, Julia Sopena-Falco, Vikrant Parihar
    World Journal of Meta-Analysis.2021; 9(2): 139.     CrossRef
  • Reply
    Hye Won Lee, Beom Kyung Kim
    Clinical Gastroenterology and Hepatology.2020; 18(1): 264.     CrossRef
  • Potential etiology, prevalence of cirrhosis, and mode of detection among patients with non-B non-C hepatocellular carcinoma in Korea
    Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
    The Korean Journal of Internal Medicine.2020; 35(1): 65.     CrossRef
  • Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: A nationwide cohort study
    Chai Yeong Hong, Dong Hyun Sinn, Danbee Kang, Seung Woon Paik, Eliseo Guallar, Juhee Cho, Geum‐Youn Gwak
    Journal of Viral Hepatitis.2020; 27(9): 896.     CrossRef
  • RETRACTED ARTICLE: Baicalin relieves inflammation stimulated by lipopolysaccharide via upregulating TUG1 in liver cells
    Yanqiu Huang, Mengyan Sun, Xuefang Yang, Aiyu Ma, Yujie Ma, Aiying Zhao
    Journal of Physiology and Biochemistry.2019; 75(4): 463.     CrossRef
  • The risk of hepatocellular carcinoma among chronic hepatitis B virus‐infected patients outside current treatment criteria
    Dong Hyun Sinn, Sung Eun Kim, Beom Kyung Kim, Ji Hoon Kim, Moon Seok Choi
    Journal of Viral Hepatitis.2019; 26(12): 1465.     CrossRef
  • Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study
    Danbee Kang, Im-Ryung Kim, Eun-Kyung Choi, Young Hyuck Im, Yeon Hee Park, Jin Seok Ahn, Jeong Eon Lee, Seok Jin Nam, Hae Kwang Lee, Ji-Hye Park, Dong-Youn Lee, Mario E. Lacouture, Eliseo Guallar, Juhee Cho
    The Oncologist.2019; 24(3): 414.     CrossRef
  • Practical guidelines for performing laparoscopic liver resection based on the second international laparoscopic liver consensus conference
    Jai Young Cho, Ho-Seong Han, Go Wakabayashi, Olivier Soubrane, David Geller, Nicholas O'Rourke, Joseph Buell, Daniel Cherqui
    Surgical Oncology.2018; 27(1): A5.     CrossRef
  • Interleukin-6-174 promoter polymorphism and susceptibility to hepatitis B virus infection in Javanese individuals
    A A Prasetyo, M Marwoto, W Monica
    IOP Conference Series: Materials Science and Engineering.2018; 434: 012114.     CrossRef
  • 12,330 View
  • 249 Download
  • 22 Web of Science
  • Crossref

Case Report

Hepatic neoplasm

A case of ruptured hepatic angiomyolipoma in a young male
Sun Hwa Kim, Tae Wook Kang, Kyunghee Lim, Hyun Sung Joh, Jiseok Kang, Dong Hyun Sinn
Clin Mol Hepatol 2017;23(2):179-183.
Published online April 28, 2017
DOI: https://doi.org/10.3350/cmh.2016.0027
A 31-year-old male visited a local hospital due to sudden-onset severe abdominal pain. Abdominal computed tomography revealed a solid cystic mass with a size of approximately 12 cm and exhibiting both hemorrhage and fluid collection in the pelvic cavity. Emergency angiography and embolization were performed, and a large hepatic tumor was subsequently surgically resected. The tumor cells stained positive for human melanoma black-45 and smooth-muscle actin, and the pathologic diagnosis was hepatic angiomyolipoma. This case report also discusses the spontaneous rupture of a hepatic angiomyolipoma.

Citations

Citations to this article as recorded by  Crossref logo
  • Abdominal Manifestations of Tuberous Sclerosis Complex
    Muhammad Nabeel Akram, Kai Xue, Kaustubh G. Shiralkar, Steven S. Chua
    Applied Radiology.2025; 54(2): 21.     CrossRef
  • A Resected Case of Hepatic Angiomyolipoma with Tumor Hemorrhage and Undetectable Fat Causing Diagnostic Difficulty
    Yumeo Tateyama, Yuichi Yamazaki, Ayaka Katayama, Tatsuma Murakami, Hiroki Tojima, Kenichiro Araki, Takaaki Sano, Ken Shirabe, Toshio Uraoka
    Surgical Case Reports.2025; 11(1): n/a.     CrossRef
  • Case of Hepatic Angiomyolipoma: An Unusual Hepatic Lesion with a Review of Diagnostic and Management Challenges
    Bushra Kurban, Deepti Shukla, Shamas Zaman, Muhannad Al Okla
    The Korean Journal of Gastroenterology.2025; 85(3): 404.     CrossRef
  • Surgical management of liver angiomyolipoma: eighteen years of experience from a single-reference center
    Oğuzhan Şal, Beslen Göksoy, Anas Al Hajeh, Leman Damla Ercan, Melek Büyük, Kürşat Rahmi Serin
    HPB.2024; 26(1): 156.     CrossRef
  • Hepatic Angiomyolipoma With Predominant Lipomatous Component: A Rare Entity
    Jaweria Pervaiz, Samina Zaman, Sohaib Khalid, Zubaria Rafique, Rida Noor
    Cureus.2024;[Epub]     CrossRef
  • Hepatic perivascular epithelioid cell tumors: The importance of preoperative diagnosis
    Shuai Yan, Jia-Jie Lu, Lin Chen, Wei-Hua Cai, Jin-Zhu Wu
    World Journal of Gastroenterology.2024; 30(13): 1926.     CrossRef
  • Minimally Invasive Image-Guided Procedures for Benign Liver Lesions
    Fiza M. Khan, Nariman Nezami, Florian Stumpf, Tyler A. Smith, Margarita Revizin, Adam Fang, Mohammad F. Loya, Rahul A. Sheth, Steven Yevich, Peiman Habibillahi
    Digestive Disease Interventions.2023; 07(03): 202.     CrossRef
  • A rare case of giant hepatic angiomyolipoma with subcapsular rupture
    Cuiting Wu, Yang Yang, Feng Tian, Yuan Xu, Qiang Qu
    Frontiers in Surgery.2023;[Epub]     CrossRef
  • Transcatheter arterial embolization followed by laparoscopic anatomic hepatectomy for spontaneous rupture of a giant hepatic angiomyolipoma: a case report
    Jianjun Wang, Ruizi Shi, Hua Luo, Pei Yang, Huiwen Luo, Ziqing Gao, Decai Wang, Xintao Zeng
    Frontiers in Surgery.2023;[Epub]     CrossRef
  • Giant hepatic angiomyolipoma presenting with severe anemia: A surgical case report and review of literature
    Cong Long Nguyen, Ham Hoi Nguyen, Tuan Hiep Luong, Nghe Tinh Nguyen, Van Khang Le, Truong Khanh Vu
    International Journal of Surgery Case Reports.2022; 94: 107087.     CrossRef
  • Retrospective analysis of hepatic perivascular epithelioid cell tumour (PEComa) in a single centre for clinical diagnosis and treatment clinical diagnosis and treatment of hepatic PEComa
    Xiao Yang, Qingyuan Wang, Xiao Zhou, Haoming Zhou, Wenbo Jia, Chunyang Hu, Jian Chu, Lianbao Kong
    Medicine.2022; 101(25): e29506.     CrossRef
  • Clinical characteristics and outcomes of patients with hepatic angiomyolipoma: A literature review
    Paul Calame, Gaëlle Tyrode, Delphine Weil Verhoeven, Sophie Félix, Anne Julia Klompenhouwer, Vincent Di Martino, Eric Delabrousse, Thierry Thévenot
    World Journal of Gastroenterology.2021; 27(19): 2299.     CrossRef
  • Laparoscopic hepatectomy for hepatic angiomyolipoma with preoperative diagnosis of other malignancy: a report of 2 cases
    Yoh Asahi, Toshiya Kamiyama, Tatsuya Orimo, Shingo Shimada, Akihisa Nagatsu, Yuzuru Sakamoto, Chihiro Ishizuka, Kazuya Hamada, Hirofumi Kamachi, Emi Takakuwa, Tomoko Mitsuhashi, Akinobu Taketomi
    Surgical Case Reports.2021;[Epub]     CrossRef
  • Diagnosis and surgical treatment of a rare hepatic angiomyolipoma with internal hemorrhage
    Mizelle D'Silva, Hee Young Na, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Moonhwan Kim
    Annals of Hepato-Biliary-Pancreatic Surgery.2021; 25(4): 532.     CrossRef
  • Hepatic angiomyolipoma: an international multicenter analysis on diagnosis, management and outcome
    Anne J. Klompenhouwer, Roy S. Dwarkasing, Michael Doukas, Silvia Pellegrino, Valerie Vilgrain, Valerie Paradis, Olivier Soubrane, Joal D. Beane, David A. Geller, Michael A. Nalesnik, Verena Tripke, Hauke Lang, Moritz Schmelzle, Johann Pratschke, Wenzel Sc
    HPB.2020; 22(4): 622.     CrossRef
  • Imaging hepatic angiomyolipomas: key features and avoiding errors
    J. Seow, M. McGill, W. Wang, P. Smith, M. Goodwin
    Clinical Radiology.2020; 75(2): 88.     CrossRef
  • 14,007 View
  • 122 Download
  • 15 Web of Science
  • Crossref

Original Articles

Hepatic neoplasm

The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE
Jung Hee Kim, Dong Hyun Sinn, Sung Wook Shin, Sung Ki Cho, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Moon Seok Choi
Clin Mol Hepatol 2017;23(1):42-50.
Published online March 7, 2017
DOI: https://doi.org/10.3350/cmh.2016.0058
Background/Aims
We investigated the outcomes of early-stage hepatocellular carcinoma (HCC) patients who showed a complete response (CR) to initial transarterial chemoembolization (TACE), with a focus on the role of scheduled TACE repetition.
Methods
A total of 178 patients with early-stage HCC who were initially treated with TACE and showed a CR based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria on one month follow-up computed tomography (CT) were analyzed. Among them, 90 patients underwent scheduled repetition of TACE in the absence of viable tumor on CT.
Results
During a median follow-up period of 4.6 years (range: 0.4-8.8 years), mortality was observed in 71 patients (39.9%). The overall recurrence-free and local recurrence-free survival rates at 1 year were 44.4% and 56.2%. In the multivariable model, scheduled repetition of TACE was an independent factor associated with survival (hazard ratio [95% confidence interval]: 0.56 [0.34-0.93], P=0.025). When stratified using Barcelona clinic liver cancer (BCLC) stage, scheduled repetition of TACE was associated with a favorable survival rate in BCLC stage A patients, but not in BCLC 0 patients.
Conclusions
Scheduled repetition of TACE was associated with better survival for early-stage HCC patients showing a CR after initial TACE, especially in BCLC stage A patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Molecular mechanisms of TACE refractoriness: Directions for improvement of the TACE procedure
    Jiahao Li, Yingnan Liu, Ruipeng Zheng, Chao Qu, Jiarui Li
    Life Sciences.2024; 342: 122540.     CrossRef
  • Local recurrence following complete radiologic response in patients treated with transarterial chemoembolization for hepatocellular carcinoma
    Shamar Young, Tina Sanghvi, Sandeep Sharma, Cameron Richardson, Nathan Rubin, Masters Richards, Donna D'Souza, Siobhan Flanagan, Jafar Golzarian
    Diagnostic and Interventional Imaging.2022; 103(3): 143.     CrossRef
  • Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients
    Woo Jin Jung, Sangmi Jang, Won Joon Choi, Jaewon Park, Gwang Hyeon Choi, Eun Sun Jang, Sook-Hyang Jeong, Won Seok Choi, Jae Hwan Lee, Chang Jin Yoon, Jin-Wook Kim
    Scientific Reports.2022;[Epub]     CrossRef
  • Research Progress on the Predictive Value of Early Curative Effect after TACE for Hepatocellular Carcinoma
    志祥 刘
    Advances in Clinical Medicine.2022; 12(11): 10342.     CrossRef
  • Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma
    Jae Seung Lee, Young Eun Chon, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Wonseok Kang, Moon Seok Choi, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Hwi Young Kim, Tae Hun Kim, Kwon Yoo,
    Yonsei Medical Journal.2021; 62(1): 12.     CrossRef
  • Association between Time to Local Tumor Control and Treatment Outcomes Following Repeated Loco-Regional Treatment Session in Patients with Hepatocellular Carcinoma: A Retrospective, Single-Center Study
    Krzysztof Bartnik, Wacław Hołówko, Olgierd Rowiński
    Life.2021; 11(10): 1062.     CrossRef
  • Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
    David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Cancers.2021; 14(1): 67.     CrossRef
  • Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection
    Mi Young Jeon, Hye Soo Kim, Tae Seop Lim, Dai Hoon Han, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Gi Hong Choi, Jin Sub Choi, Kwang-Hyub Han, Seung Up Kim, Gianfranco D. Alpini
    PLOS ONE.2019; 14(4): e0214613.     CrossRef
  • Long-Term Efficacy and Safety of Partial Splenic Embolization in Hepatocellular Carcinoma Patients with Thrombocytopenia Who Underwent Transarterial Chemoembolization
    Nam Hee Kim, Hong Joo Kim, Yong Kyun Cho, Hyun Pyo Hong, Byung Ik Kim
    Journal of Korean Medical Science.2019;[Epub]     CrossRef
  • A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study
    Shintaro Shiba, Kei Shibuya, Hiroyuki Katoh, Takuya Kaminuma, Masaya Miyazaki, Satoru Kakizaki, Ken Shirabe, Tatsuya Ohno, Takashi Nakano
    Radiation Oncology.2019;[Epub]     CrossRef
  • Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma
    Yaojun Zhang, Mengping Zhang, Minshan Chen, Jie Mei, Li Xu, Rongping Guo, Xiaojun Lin, Jiaping Li, Zhenwei Peng
    JAMA Network Open.2018; 1(6): e183213.     CrossRef
  • 13,148 View
  • 226 Download
  • 13 Web of Science
  • Crossref

Hepatic neoplasm

Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma
Jun Young Kim, Dong Hyun Sinn, Geum-Youn Gwak, Gyu-Seong Choi, Aldosri Meshal Saleh, Jae-Won Joh, Sung Ki Cho, Sung Wook Shin, Keumhee Chough Carriere, Joong Hyun Ahn, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Clin Mol Hepatol 2016;22(2):250-258.
Published online June 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0015
Background/Aims
Several studies have suggested that surgical resection (SR) can provide a survival benefit over transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) at the intermediate stage according to the Barcelona Clinic Liver Cancer (BCLC) staging system. However, the criteria for SR remain to be determined. This study compared the long-term outcome of intermediate-stage HCC patients treated by either TACE or SR as a primary treatment modality, with the aim of identifying the patient subgroup that gained a survival benefit by either modality.
Methods
In total, 277 BCLC intermediate-stage HCC patients treated by either TACE (N=225) or SR (N=52) were analyzed.
Results
The overall median survival time was significantly better for SR than TACE (61 vs. 30 months, P=0.002). Decisiontree analysis divided patients into seven nodes based on tumor size and number, serum alpha-fetoprotein (AFP) level, and Child-Pugh score, and these were then simplified into four subgroups (B1–B4) based on similarities in the overall hazard rate. SR provided a significant survival benefit in subgroup B2, characterized by ‘oligo’ (2–4) nodules of intermediate size (5–10 cm) when the AFP levels was <400 ng/ml, or ‘oligo’ (2–4) nodules of small to intermediate size (<10 cm) plus a Child-Pugh score of 5 when the AFP level was ≥400 ng/mL (median survival 73 vs. 28 months for SR vs. TACE respectively; P=0.014). The survival rate did not differ significantly between SR and TACE in the other subgroups (B1 and B3).
Conclusions
SR provided a survival benefit over TACE in intermediate-stage HCC, especially for patients meeting certain criteria. Re-establishing the criteria for optimal treatment modalities in this stage of HCC is needed to improve survival rates.

Citations

Citations to this article as recorded by  Crossref logo
  • Long-term results of surgical treatment in patients with intermediate stage (BCLC B) hepatocellular carcinoma: a single-center retrospective study
    B. I. Sakibov, D. V. Podluzhnyi, Yu. I. Patyutko, O. A. Egenov, N. E. Kudashkin
    Surgery and Oncology.2025; 15(2): 62.     CrossRef
  • Efficacy of therapies for intermediate-stage hepatocellular carcinoma: systematic review and network meta-analysis
    Shaoqi Zong, Yifan Yang, Zifei Yin, Lanyun Feng, Kun Wang, Hao Chen, Zhen Chen, Zhiqiang Meng, Yongqiang Hua
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Efficacy of postoperative adjuvant hepatic artery infusion chemotherapy for hepatocellular carcinoma in microvascular invasion: a propensity-matched score
    Xu Feng, Xinhua Wu, Kai Chen, Yupei Ao, Zhengrong Shi, Yixuan Gong
    Frontiers in Surgery.2025;[Epub]     CrossRef
  • Conversion Resection or Direct Resection for Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicentre Study
    Ying Zhou, Haiqing Wang, Jiayi Wu, Junyi Shen, Ji Ma, Qiu Li, Weixia Chen, Wusheng Lu, Xielin Feng, Maolin Yan, Tianfu Wen, Xiaoyun Zhang
    Liver Cancer.2025; : 1.     CrossRef
  • Identification of patients with favorable prognosis after resection in intermediate-stage-hepatocellular carcinoma
    Han Ah Lee, Minjong Lee, Jeong-Ju Yoo, Ho Soo Chun, Yewan Park, Hwi Young Kim, Tae Hun Kim, Yeon Seok Seo, Dong Hyun Sinn
    International Journal of Surgery.2024; 110(2): 1008.     CrossRef
  • Application of the Left Lateral Decubitus Position in Laparoscopic Right Posterior Lobectomy
    Dong-Fang Huang, Jian-Bo Xu, Ye-Mu Du, Ye-Bo Wang, Ding-Hua Zhou
    Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2024; 34(2): 178.     CrossRef
  • The role of resection in hepatocellular carcinoma BCLC stage B: A multi-institutional patient-level meta-analysis and systematic review
    Victor Lopez-Lopez, Fabian Kalt, Jian-Hong Zhong, Cristiano Guidetti, Paolo Magistri, Fabrizio Di Benedetto, Arndt Weinmann, Jens Mittler, Hauke Lang, Rohini Sharma, Mathew Vithayathil, Samir Tariq, Patricia Sánchez-Velázquez, Gianluca Rompianesi, Roberto
    Langenbeck's Archives of Surgery.2024;[Epub]     CrossRef
  • Prognostic performance of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging systems in hepatocellular carcinoma
    Mohamed Kohla, Reham Ashour, Hossam Taha, Osama El-Abd, Maher Osman, Mai Abozeid, Sally Waheed ELKhadry
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Intermediate hepatocellular carcinoma: new horizons and prospects for our patients
    Federica Lo Prinzi, Federico Rossari, Marianna Silletta, Silvia Foti, Silvia Camera, Francesco Vitiello, Elisabeth Amadeo, Francesco De Cobelli, Luca Aldrighetti, Margherita Rimini, Andrea Casadei-Gardini
    Expert Review of Gastroenterology & Hepatology.2024; 18(10): 661.     CrossRef
  • Surgical resection for large hepatocellular carcinoma and those beyond BCLC: systematic review with proposed management algorithm
    Saneya Pandrowala, Shraddha Patkar, Mahesh Goel, Darius Mirza, S. K. Mathur
    Langenbeck's Archives of Surgery.2023;[Epub]     CrossRef
  • Liver resection versus transarterial chemoembolisation for the treatment of intermediate hepatocellular carcinoma: a systematic review and meta-analysis
    Aleksandar Bogdanovic, Jelena Djokic Kovac, Predrag Zdujic, Uros Djindjic, Vladimir Dugalic
    International Journal of Surgery.2023; 109(5): 1439.     CrossRef
  • Efficacy and safety of lenvatinib–transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospecti
    Ko Oshita, Tsuyoshi Kobayashi, Yosuke Namba, Sotaro Fukuhara, Keiso Matsubara, Daisuke Takei, Ryosuke Nakano, Wataru Okamoto, Hiroshi Sakai, Naoki Tanimine, Takashi Nakahara, Shintaro Kuroda, Hiroyuki Tahara, Masahiro Ohira, Tomokazu Kawaoka, Kentaro Ide,
    BMJ Open.2023; 13(10): e073797.     CrossRef
  • A retrospective study of transarterial chemoembolization (TACE) combined with lenvatinib compared with TACE monotherapy for BCLC B2 stage hepatocellular carcinoma
    Junning Liu, Shu Yan, Guangnian Zhang, Linfeng Yang, Song Wei, Pengsheng Yi
    Oncology Letters.2023;[Epub]     CrossRef
  • Novel predictive nomograms based on aspartate aminotransferase‑to‑platelet ratio index for hepatocellular carcinoma with post‑operative adjuvant transarterial chemoembolization
    Qinghua Shu, Nannan Zhang, Jianbo Han, Xiaopeng Yan, Bowen Sha, Liang Zhao, Yongxiang Yi, Yufeng Zhang
    Oncology Letters.2023;[Epub]     CrossRef
  • Selecting the Best Approach for the Treatment of Multiple Non-Metastatic Hepatocellular Carcinoma
    Gianluca Cassese, Ho-Seong Han, Jai Young Cho, Hae-Won Lee, Boram Lee, Roberto Ivan Troisi
    Cancers.2022; 14(23): 5997.     CrossRef
  • The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma After Radical Hepatectomy: a Propensity Score-Matching Study
    Lei Wang, Chunhong Xiao, Ren Wang, Jingbo Chen, Weiping Zhou, Jingfeng Liu, Nanping Lin, Kongying Lin
    Journal of Gastrointestinal Surgery.2021; 25(5): 1172.     CrossRef
  • Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study
    Hye Kyung Hyun, Eun Ju Cho, Soo Young Park, Young Mi Hong, Soon Sun Kim, Hwi Young Kim, Nae-Yun Heo, Jung Gil Park, Dong Hyun Sinn, Wonseok Kang, Song Won Jeong, Myeong Jun Song, Hana Park, Danbi Lee, Yong Sun Lee, Sung Bum Cho, Chan Sik An, Hyung Jin Rhe
    Digestive Diseases and Sciences.2021; 66(7): 2427.     CrossRef
  • Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma
    Xiang-Ke Niu, Xiao-Feng He
    World Journal of Gastroenterology.2021; 27(2): 189.     CrossRef
  • Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma
    Jae Seung Lee, Young Eun Chon, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Wonseok Kang, Moon Seok Choi, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Hwi Young Kim, Tae Hun Kim, Kwon Yoo,
    Yonsei Medical Journal.2021; 62(1): 12.     CrossRef
  • Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization
    Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Current Oncology.2021; 28(1): 965.     CrossRef
  • Prediction of Patient Survival Following Hepatic Resection in Early-Stage Hepatocellular Carcinoma with Indexed Ratios of Aspartate Aminotransferase to Platelets: A Retrospective Cohort Study
    Jian Huang, Yun Yang, Yong Xia, Fu-Chen Liu, Lei Liu, Peng Zhu, Sheng-Xian Yuan, Fang-Ming Gu, Si-Yuan Fu, Wei-Ping Zhou, Hui Liu, Bei-Ge Jiang, Ze-Ya Pan
    Cancer Management and Research.2021; Volume 13: 1733.     CrossRef
  • Efficacy of Combined Therapy with Drug-Eluting Beads-Transcatheter Arterial Chemoembolization Followed by Conventional Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multi-Center Study
    Asahiro Morishita, Joji Tani, Takako Nomura, Kei Takuma, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Koji Fujita, Tingting Shi, Hiroki Yamana, Takanori Matsui, Tadayuki Takata, Takayuki Sanomura, Yoshihiro Nishiyama, Takashi Himoto, Tetsu Tomonari, Akio Mo
    Cancers.2021; 13(18): 4605.     CrossRef
  • An observational study on long‐term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate
    Tae Seop Lim, Jae Seung Lee, Beom Kyung Kim, Hye Won Lee, Mi Young Jeon, Seung Up Kim, Jun Yong Park, Do Young Kim, Kwang‐Hyub Han, Sang Hoon Ahn
    Journal of Viral Hepatitis.2020; 27(3): 316.     CrossRef
  • Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review
    Biao Yang, Jie Liang, ZiYu Qu, FangYun Yang, ZhengYin Liao, HongFeng Gou, Gianfranco D. Alpini
    PLOS ONE.2020; 15(2): e0227475.     CrossRef
  • Appraisal of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B
    Jeong-Ju Yoo, Su Jong Yu, Bora Lee, Eun Ju Cho, Jeong-Hoon Lee, Sang Gyune Kim, Yoon Jun Kim, Young Seok Kim, Jung-Hwan Yoon
    Gut and Liver.2020; 14(3): 377.     CrossRef
  • Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study
    Mi Young Jeon, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Eun Ju Cho, Seung Up Kim
    Gut and Liver.2020; 14(4): 477.     CrossRef
  • Comparison of Transcatheter Arterial Chemoembolization-Radiofrequency Ablation and Transcatheter Arterial Chemoembolization Alone for Advanced Hepatocellular Carcinoma with Macrovascular Invasion Using Propensity Score Analysis: A Retrospective Cohort Stu
    Yao Liu, Yuxin Li, Fangyuan Gao, Qun Zhang, Xue Yang, Bingbing Zhu, Shuaishuai Niu, Yunyi Huang, Ying Hu, Wei Li, Xianbo Wang
    Journal of Oncology.2020; 2020: 1.     CrossRef
  • Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria
    Joo Hyun Oh, Dong Hyun Sinn, Gyu-Seong Choi, Jong Man Kim, Jae-Won Joh, Tae Wook Kang, Dongho Hyun, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Moon Seok Choi
    Annals of Surgical Treatment and Research.2020; 99(4): 238.     CrossRef
  • Is Transarterial Chemoembolization Only Treatment Option in Patients with Intermediate Stage of Hepatocellular Carcinoma?: in Perspectives of Surgery
    Ji Young Lim, Minjong Lee, Tae Hun Kim
    Journal of Liver Cancer.2020; 20(2): 113.     CrossRef
  • A Five‐Gene Signature for Recurrence Prediction of Hepatocellular Carcinoma Patients
    Zeyu Wang, Ningning Zhang, Jiayu Lv, Cuihua Ma, Jie Gu, Yawei Du, Yibo Qiu, Zhiguang Zhang, Man Li, Yong Jiang, Jianqiu Zhao, Huiqin Du, Zhiwei Zhang, Wei Lu, Yan Zhang, Luca Miele
    BioMed Research International.2020;[Epub]     CrossRef
  • Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma
    Qunfang Zhou, Fei Tuo, Ruixia Li, Xiaohui Wang, Juncheng Wang, Zhimei Huang, Minshan Chen, Jinhua Huang
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization
    Jae Seung Lee, Hong Jun Choi, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Song-Ee Baek, Yong Eun Chung, Mi-Suk Park, Myeong-Jin Kim, Hyungjin Rhee, Seung Up Kim
    Gut and Liver.2020; 14(6): 765.     CrossRef
  • Comparison between hepatocellular carcinoma prognostic scores: A 10-year single-center experience and brief review of the current literature
    Michele Campigotto, Mauro Giuffrè, Anna Colombo, Alessia Visintin, Alessandro Aversano, Martina Budel, Flora Masutti, Cristiana Abazia, Lory Saveria Crocé
    World Journal of Hepatology.2020; 12(12): 1239.     CrossRef
  • Comparison of Partial Hepatectomy and Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Ismail Labgaa, Patrick Taffé, David Martin, Daniel Clerc, Myron Schwartz, Norihiro Kokudo, Alban Denys, Nermin Halkic, Nicolas Demartines, Emmanuel Melloul
    Liver Cancer.2020; 9(2): 138.     CrossRef
  • Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection
    Mi Young Jeon, Hye Soo Kim, Tae Seop Lim, Dai Hoon Han, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Gi Hong Choi, Jin Sub Choi, Kwang-Hyub Han, Seung Up Kim, Gianfranco D. Alpini
    PLOS ONE.2019; 14(4): e0214613.     CrossRef
  • Clinical Relevance of Reductive Hepatectomy for Barcelona Clinic Liver Cancer Stages B and C Advanced Hepatocellular Carcinoma: A Single‐Center Experience of 102 Patients
    Shohei Komatsu, Masahiro Kido, Motofumi Tanaka, Kaori Kuramitsu, ·Daisuke Tsugawa, Masahide Awazu, Hidetoshi Gon, Hirochika Toyama, Kimihiko Ueno, Takumi Fukumoto
    World Journal of Surgery.2019; 43(10): 2571.     CrossRef
  • Hepatocellular carcinoma staging systems: Hong Kong liver cancer vs Barcelona clinic liver cancer in a Western population
    Laura Bainy Rodrigues de Freitas, Larisse Longo, Deivid Santos, Ivana Grivicich, Mário Reis Álvares-da-Silva
    World Journal of Hepatology.2019; 11(9): 689.     CrossRef
  • Surgical resection versus transarterial chemoembolization for BCLC intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis
    Lei Liang, Hao Xing, Han Zhang, Jianhong Zhong, Chao Li, Wan Yee Lau, Mengchao Wu, Feng Shen, Tian Yang
    HPB.2018; 20(2): 110.     CrossRef
  • Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms
    Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Juneyoung Lee, Hae Rim Kim, Yang Jae Yoo, Tae Suk Kim, Seong Hee Kang, Sang Jun Suh, Moon Kyung Joo, Young Kul Jung, Beom Jae Lee, Hyung Joon Yim, Jong Eun Yeon, Jae Seon Kim, Jong-Jae Park, Soon Ho Um, Young-Tae
    Gut and Liver.2018; 12(1): 94.     CrossRef
  • Chemoembolization related to good survival for selected patients with hepatocellular carcinoma invading segmental portal vein
    Jin Hyoung Kim, Ju Hyun Shim, Hyun‐Ki Yoon, Heung‐Kyu Ko, Jong Woo Kim, Dong Il Gwon
    Liver International.2018; 38(9): 1646.     CrossRef
  • Hepatic resection compared to chemoembolization in intermediate‐ to advanced‐stage hepatocellular carcinoma: A meta‐analysis of high‐quality studies
    Myung Han Hyun, Young‐Sun Lee, Ji Hoon Kim, Chan Uk Lee, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun
    Hepatology.2018; 68(3): 977.     CrossRef
  • Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma
    Biao Yang, Bo Zheng, MaoNan Yang, Zhu Zeng, FangYun Yang, Ji Pu, ChunLin Li, ZhengYin Liao
    Hepatology International.2018; 12(5): 417.     CrossRef
  • Impact of local tumor lesion treatments and preoperative indicators on the survival of patients with small hepatocellular carcinomas
    Yanyan Wei, Feng Dai, Yongxiang Yi, Wei Ye, Wei Zhao
    Oncology Letters.2018;[Epub]     CrossRef
  • Outcomes following liver resection for multinodular Barcelona Clinic Liver Cancer‑B hepatocellular carcinoma
    Satoshi Matsukuma, Kazuhiko Sakamoto, Yoshihiro Tokuhisa, Yukio Tokumitsu, Hiroto Matsui, Shinsuke Kanekiyo, Shinobu Tomochika, Michihisa Iida, Nobuaki Suzuki, Shigeru Takeda, Tomio Ueno, Hiroshi Wada, Shogo Kobayashi, Issei Saeki, Hidetoshi Eguchi, Masat
    Oncology Letters.2018;[Epub]     CrossRef
  • Therapeutic priorities for solitary large hepatocellular carcinoma in a hepatitis B virus endemic area; an analysis of a nationwide cancer registry database
    Young‐Joo Jin, Jin‐Woo Lee
    Journal of Surgical Oncology.2017; 115(4): 407.     CrossRef
  • Validity of the Barcelona Clinic Liver Cancer and Hong Kong Liver Cancer staging systems for hepatocellular carcinoma in Singapore
    Li Kim E. Selby, Rosanna X. Y. Tay, Winston W. L. Woon, Jee Keem Low, Wang Bei, Vishalkumar G. Shelat, Tony C. Y. Pang, Sameer P. Junnarkar
    Journal of Hepato-Biliary-Pancreatic Sciences.2017; 24(3): 143.     CrossRef
  • Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B
    Yuri Cho, Dong Hyun Sinn, Su Jong Yu, Geum Youn Gwak, Ji Hoon Kim, Yang Jae Yoo, Dae Won Jun, Tae Yeob Kim, Hyo Young Lee, Eun Ju Cho, Jeong-Hoon Lee, Yoon Jun Kim, Jung-Hwan Yoon, Sheng-Nan Lu
    PLOS ONE.2016; 11(11): e0165722.     CrossRef
  • 15,137 View
  • 206 Download
  • 46 Web of Science
  • Crossref

Viral hepatitis

Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure
Jung Min Ha, Won Sohn, Ju Yeon Cho, Jeung Hui Pyo, Kyu Choi, Dong Hyun Sinn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Chul Koh, Seung Woon Paik, Byung Chul Yoo, Yong-Han Paik
Clin Mol Hepatol 2015;21(3):232-241.
Published online September 30, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.3.232
Background/Aims

Hepatitis-B-related acute-on-chronic liver failure has a poor prognosis. However, the advent of potent oral antiviral agents means that some patients can now recover with medical treatment. We aimed to identify the prognostic factors for hepatitis-B-related acute-on-chronic liver failure including the initial as well as the dynamically changing clinical parameters during admission.

Methods

Sixty-seven patients were retrospectively enrolled from 2003 to 2012 at Samsung Medical Center. The patients were classified into three categories: Recovery group (n=23), Liver transplantation group (n=28), and Death group (n=16). The Liver transplantation and Death groups were combined into an Unfavorable prognosis group. We analyzed the prognostic factors including the Model for End-Stage Liver Disease (MELD) scores determined at 3-day intervals.

Results

A multivariable analysis showed that the unfavorable prognostic factors were a high initial MELD score (≥28) (odds ratio [OR] =6.64, p=0.015), moderate-to-severe ascites at admission (OR=6.71, P=0.012), and the aggravation of hepatic encephalopathy during hospitalization (≥grade III) (OR=15.41, P=0.013). Compared with the baseline level, significant reductions in the MELD scores were observed on the 7th day after admission in the Recovery group (P=0.016).

Conclusions

Dynamic changes in clinical parameters during admission are useful prognostic factors for hepatitis-B-related acute-on-chronic liver failure.

Citations

Citations to this article as recorded by  Crossref logo
  • Plasma galectin-3 can be considered as a non-invasive marker to predict the prognosis of ACLF patients with new typing
    Li Bai, Wang Lu, Qi Yang, Xiaoxuan Liu, Yu Chen, Zhongping Duan
    Scientific Reports.2025;[Epub]     CrossRef
  • Construction of a novel prognostic scoring model for HBV-ACLF liver failure based on dynamic data
    Qun Cai, Hao Wang, Mingyan Zhu, Yixin Xiao, Tingting Zhuo
    Scientific Reports.2024;[Epub]     CrossRef
  • PLT Counts as a Predictive Marker after Plasma Exchange in Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure
    Xue Li, Hao Li, Yucui Zhu, Huaqian Xu, Shanhong Tang
    Journal of Clinical Medicine.2023; 12(3): 851.     CrossRef
  • Falla hepática aguda sobre crónica: análisis de una serie de casos y revisión de la literatura
    Jhon Edwar García-Rueda, Ricardo Londoño-García, Tomás Marín-Cuartas, Juan Esteban Hernández-Abaunza, Sebastián Osorio-Rico, Angélica María Bermúdez-Flórez, Juan Carlos Restrepo-Gutiérrez
    Hepatología.2022; : 72.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2022; 28(2): 276.     CrossRef
  • A dynamic prediction model for prognosis of acute-on-chronic liver failure based on the trend of clinical indicators
    Zhenjun Yu, Yu Zhang, Yingying Cao, Manman Xu, Shaoli You, Yu Chen, Bing Zhu, Ming Kong, Fangjiao Song, Shaojie Xin, Zhongping Duan, Tao Han
    Scientific Reports.2021;[Epub]     CrossRef
  • Clinical Course and Outcome Patterns of Acute-on-chronic Liver Failure: A Multicenter Retrospective Cohort Study
    Man-Man Xu, Ming Kong, Peng-Fei Yu, Ying-Ying Cao, Fang Liu, Bing Zhu, Yi-Zhi Zhang, Wang Lu, Huai-Bin Zou, Bin-Wei Duan, Shao-Li You, Shao-Jie Xin, Tao Han, Zhong-Ping Duan, Yu Chen
    Journal of Clinical and Translational Hepatology.2021; 000(000): 000.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2019; 25(2): 93.     CrossRef
  • A Dynamic Model for Predicting Outcome in Patients with HBV Related Acute-On-Chronic Liver Failure
    Wei Lin, Jing Zhang, Xiaohui Liu, Hongqun Liu, Jinqiu He, Ming Li, Shuqin Zhang, Hong Chen, Changqing Zhang, Wenfang Wu, Chenggang Jin, Samuel S. Lee, Zhongping Duan, Yuexin Zhang
    Annals of Hepatology.2018; 17(3): 392.     CrossRef
  • 11,506 View
  • 96 Download
  • 9 Web of Science
  • Crossref

Case Report

Viral hepatitis

Pure red-cell aplasia and autoimmune hemolytic anemia in a patient with acute hepatitis A
Hyo Jeong Chang, Dong Hyun Sinn, Sung Gyun Cho, Tae Hoon Oh, Tae Joo Jeon, Won Chang Shin, Won Choong Choi
Clin Mol Hepatol 2014;20(2):204-207.
Published online June 30, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.2.204

Pure red cell aplasia (PRCA) and autoimmune hemolytic anemia (AIHA) have rarely been reported as an extrahepatic manifestation of acute hepatitis A (AHA). We report herein a case of AHA complicated by both PRCA and AIHA. A 49-year-old female with a diagnosis of AHA presented with severe anemia (hemoglobin level, 6.9 g/dL) during her clinical course. A diagnostic workup revealed AIHA and PRCA as the cause of the anemia. The patient was treated with an initial transfusion and corticosteroid therapy. Her anemia and liver function test were completely recovered by 9 months after the initial presentation. We review the clinical features and therapeutic strategies for this rare case of extrahepatic manifestation of AHA.

Citations

Citations to this article as recorded by  Crossref logo
  • Case Report: Acute hepatitis A virus infection presenting with direct antiglobulin test-negative autoimmune hemolytic anemia and α-thalassemia trait
    Habiba Debbabi, Eya Chakroun, Hajer Hassine, Hela Kchir, Dhouha Cherif, Haythem Yacoub, Nadia Maamouri
    F1000Research.2025; 13: 1224.     CrossRef
  • Case Report: Acute hepatitis A virus infection presenting with direct antiglobulin test-negative autoimmune hemolytic anemia and α-thalassemia trait
    Habiba Debbabi, Eya Chakroun, Hajer Hassine, Hela Kchir, Dhouha Cherif, Haythem Yacoub, Nadia Maamouri
    F1000Research.2024; 13: 1224.     CrossRef
  • Exacerbation of autoimmune hemolytic anemia associated with pure red cell aplasia after COVID-19: A case report
    Hideo Kimura, Miki Furukawa, Yutaka Shiga, Tatsuyuki Kai, Ikkoh Yasuda, Shungo Katoh, Eiichiro Sando
    Journal of Infection and Chemotherapy.2023; 29(8): 787.     CrossRef
  • Local and systemic autoimmune manifestations linked to hepatitis A infection
    M Doulberis, A Papaefthymiou, S.A. Polyzos, E Vardaka, M Tzitiridou-Chatzopoulou, D Chatzopoulos, A Koffas, V Papadopoulos, F Kyrailidi, J Kountouras
    Acta Gastro Enterologica Belgica.2023; 86(3): 429.     CrossRef
  • Pure red cell aplasia accompanied by COVID-19 successfully treated using cyclosporine
    Susumu Yamazaki, Erika Naito, Ryu Sekiya, Sanehiro Yogi, Kenichiro Komiyama, Yoshitaka Miyakawa, Makoto Nagata
    Journal of Infection and Chemotherapy.2022; 28(2): 304.     CrossRef
  • Hemolytic Anemia after Acute Hepatitis B Virus Infection: A Case Report and Systematic Review
    Takahiro Suzuki, Takeshi Okamoto, Fujimi Kawai, Shuhei Okuyama, Katsuyuki Fukuda
    Internal Medicine.2022; 61(4): 481.     CrossRef
  • Hepatitis A virus infection is complicated by both pancytopenia and autoimmune hemolytic anemia (AIHA)
    Omar Al jandale, Heba Jumah, Hasan Jamil
    Annals of Medicine and Surgery.2022; 78: 103765.     CrossRef
  • Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders
    Cristiana Bianco, Elena Coluccio, Daniele Prati, Luca Valenti
    Journal of Clinical Medicine.2021; 10(3): 423.     CrossRef
  • Coombs-negative Autoimmune Hemolytic Anemia Followed by Anti-erythropoetin Receptor Antibody-associated Pure Red Cell Aplasia: A Case Report and Review of Literature
    Mayumi Yoshimi, Yutaka Kadowaki, Yuji Kikuchi, Tsuyoshi Takahashi
    Internal Medicine.2016; 55(5): 511.     CrossRef
  • Pure Red Cell Aplasia and Autoimmune Hemolytic Anemia Sequentially Occurring in a Patient with Large Granular T-lymphocytic Leukemia
    Xuemei Qin, Yuan Yu, Shuxin Yan, Ran Wang, Xinguang Liu, Chunyan Chen
    Internal Medicine.2016; 55(11): 1491.     CrossRef
  • 11,827 View
  • 126 Download
  • 8 Web of Science
  • Crossref

Editorial

Alcohol-related liver disease

Are patients with alcohol-related fatty liver at increased risk of coronary heart disease?
Dong Hyun Sinn, Yong-Han Paik
Clin Mol Hepatol 2014;20(2):151-153.
Published online June 30, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.2.151
  • 9,144 View
  • 80 Download
Case Report

Hepatic neoplasm

Hepatoid adenocarcinoma of the stomach: an unusual case of elevated alpha-fetoprotein with prior treatment for hepatocellular carcinoma
Joon Seong Ahn, Ja Ryong Jeon, Hong Seok Yoo, Taek Kyu Park, Cheol Keun Park, Dong Hyun Sinn, Seung Woon Paik
Clin Mol Hepatol 2013;19(2):173-178.
Published online June 27, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.2.173

Hepatoid adenocarcinoma (HAC) is a rare type of extrahepatic carcinoma whose morphology is similar to that of hepatocellular carcinoma (HCC). Metachronous HCC and HAC in the same patient is extremely rare. The case of a 68-year-old man with chronic hepatitis B infection who had both HCC and HAC of the stomach is reported herein. Nine years previously this patient had been diagnosed with HCC and received a right lobectomy. HCC that recurred at the caudate lobe at 6 months after the operation was successfully treated with transarterial chemoembolization. The patient was followed up regularly thereafter without evidence of tumor recurrence for 9 years. In July 2010 his serum alpha-fetoprotein (AFP) level elevated from 6.5 ng/mL to 625.4 ng/mL, and he developed a probable single metastatic lymph node around the hepatic artery without intrahepatic lesions. Subsequent evaluation with upper endoscopy revealed a 4-cm ulcerative lesion on the antrum of the stomach. Subtotal gastrectomy was performed with lymph-node dissection. Histologic examination revealed a special type of extrahepatic AFP-producing adenocarcinoma-HAC with lymph-node metastasis-which indicates that HAC can be a cause of elevated AFP even in patients with HCC. HAC should be considered if a patient with stable HCC exhibits unusual elevation of AFP.

Citations

Citations to this article as recorded by  Crossref logo
  • A chemiluminescence immunosensor for biomarker detection based on boronic acid-modified magnetic composite microspheres
    Xiuli Wang, Leyi He, Yaoxia Li, Jia Guo, Changchun Wang
    Journal of Materials Chemistry B.2024; 12(40): 10285.     CrossRef
  • Hepatoid adenocarcinoma of the stomach effectively treated with capecitabine with oxaliplatin as adjuvant chemotherapy: A case report and literature review
    Jun Amioka, Senichiro Yanagawa, Yuji Yamamoto, Masahiro Nakahara, Shuji Yonehara, Toshio Noriyuki
    International Journal of Surgery Case Reports.2023; 112: 108963.     CrossRef
  • Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments
    Ruolan Xia, Yuwen Zhou, Yuqing Wang, Jiaming Yuan, Xuelei Ma
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • The Potential Role of Radiotherapy in the Management of Hepatoid Carcinomas of the Stomach: A Case Report
    Waqas Ilyas, Prashant Jain, Rebecca Goody, Daniel Swinson, Mohan Hingorani
    Oncology Research and Treatment.2020; 43(4): 170.     CrossRef
  • Metastatic hepatoid adenocarcinoma of the stomach: a case report and review of the literature
    Mokrani A, Behi K, Sbika W, Mghirbi F, Yahyoui Y, Letaief F, Gabsi A, Meddeb K, Ayadi M, Chraiet N, Raies H, Mezlini A
    Asploro Journal of Biomedical and Clinical Case Reports.2019; 2(2): 44.     CrossRef
  • Alpha-Fetoprotein-Secreting Gallbladder Carcinoma: a Case Report
    Guray Akturk, Ozgul Sagol, Tarkan Unek, Mucahit Ozbilgin, Tufan Egeli, Sedat Karademir, Funda Obuz, Ibrahim Kemal Astarcioglu
    Journal of Gastrointestinal Cancer.2018; 49(4): 528.     CrossRef
  • The Clinical Significance of Serum Alpha-fetoprotein in Diagnosing Hepatocellular Carcinoma in a Health Screening Population
    Young Sun Ko, Joo Hwan Bae, Dong Hyun Sinn, Geum-Youn Gwak, Wonseok Kang, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
    The Korean Journal of Gastroenterology.2017; 69(4): 232.     CrossRef
  • Chemotherapy of metastatic hepatoid adenocarcinoma: Literature review and two case reports with cisplatin etoposide
    Victor Simmet, Margot Noblecourt, Thibaut Liz�e, Benjamin Morvant, Sylvie Girault, Patrick Souli�, Olivier Capitain
    Oncology Letters.2017;[Epub]     CrossRef
  • Hepatoid adenocarcinoma of the stomach: A case report of a rare type of gastric cancer
    ZHIHONG SHEN, XIBO LIU, BAOCHUN LU, MINFENG YE
    Oncology Letters.2016; 11(2): 1077.     CrossRef
  • 10,721 View
  • 80 Download
  • Crossref